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Abstract: Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising therapeutic target in cancer
therapy. Combination chemotherapy using Tdp1 inhibitors as a component can potentially improve
therapeutic response to many chemotherapeutic regimes. A new set of usnic acid derivatives with
hydrazonothiazole pharmacophore moieties were synthesized and evaluated as Tdp1 inhibitors. Most
of these compounds were found to be potent inhibitors with IC50 values in the low nanomolar range.
The activity of the compounds was verified by binding experiments and supported by molecular
modeling. The ability of the most effective inhibitors, used at non-toxic concentrations, to sensitize
tumors to the anticancer drug topotecan was also demonstrated. The order of administration of the
inhibitor and topotecan on their synergistic effect was studied, suggesting that prior or simultaneous
introduction of the inhibitor with topotecan is the most effective.
Keywords: tyrosyl-DNA phosphodiesterase 1 (Tdp1); topotecan; topoisomerase 1; usnic acid;
molecular modeling; synergetic effect; inhibiting activity
1. Introduction
The use of DNA repair enzyme inhibitors as an adjuvant therapy to treat oncological disorders
is one of the breakthroughs in modern cancer therapies [1,2]. Inhibition of DNA repair enzymes
increases the effectiveness of chemotherapy drugs, especially for drug-resistant tumors. Tyrosyl-DNA
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phosphodiesterase 1 (Tdp1) is one of the most important DNA repair enzymes that plays a key
role in removing DNA damage caused by clinically-used antitumor drugs. Tdp1 belongs to the
phospholipase D superfamily [3] and repairs DNA damage at the 3’-end, in particular, it hydrolyzes
topomerase-cleavage complexes [4] that are formed by the action of topoisomerase 1 (Top1) inhibitors
such as camptothecin and its derivatives topotecan and irinotecan.
Several potent small molecule inhibitors of Tdp1 that inhibit the enzyme at micro- and
submicromolar levels have been reported [5–7]. These Tdp1 inhibitors include compounds of
different structural classes from synthetic, natural product, and semi-synthetic origins [5–7]. Amongst
the most potent of the synthetic Tdp1 inhibitors are a pyrrole derivative 1 [8], benzopentathiepine
2 [9], and methyl-3,4-dephostatin 3 [10] (Figure 1). Pan-DNA repair enzyme inhibitors have also
been developed. For example, compound 4 (7-azaisoquinoline derivative) inhibits three DNA repair
enzymes (Top1, Tdp1, and Tdp2) [11].
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In addition, Tdp1 inhibitors have also been found from natural sources. It has been reported that
natural products that are isolated from anamorphic fungus (e.g., compound 5, Figure 2) [12], triptamine
derivatives of bile acids 6 [13], and monoterpenoid derivatives such as 7 and 8 that are attached to
7-hydroxycoumarin [14] or adamantane fragments [15–17] all show inhibitory activity against Tdp1 in
the micromolar and submicromolar concentration ranges.
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Our previous works [18–21] revealed that derivatives of usnic acid inhibit Tdp1 in the
micro- to nanomolar concentration ranges (Figure 3). Usnic acid (2,6-diacetyl-7,9-dihydroxy-8,
9b-dimethyl-1,3(2H,9bH)-dibenzo-furandione) is a lichen metabolite and exists in two enantiomeric
forms, depending on the position of the methyl group at the chiral atom C9b. The biological activity of
both enantiomers is often very different [22–25]. Usnic acid is of interest as a platform for creating
Molecules 2019, 24, 3711 3 of 34
new pharmacological agents for several reasons. First, usnic acid has a broad spectrum of intrinsic
biological properties. Second, it has a unique structure with a dibenzofuran backbone containing a
large number of different functional groups available for modification. Third, usnic acid is widespread
in different types of lichens. Finally, the procedure for the isolation of usnic acid from raw materials
is simple, and the optical purity of the extracted compound is often very high. Usnic acid refers to
substances of class III toxicity (moderately toxic) with an LD50 in mice of 838 mg/kg (Registry of
Toxic Effects of Chemical Substances) and cytotoxicity in range of 10–100 µM [23]. Numerous studies
indicate a significant decrease in the cytotoxicity of compounds (3–10 times) during the transition from
the parent usnic acid to its derivatives [22–24].
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For ena inic derivatives of usnic acid 9a,b, they were found to inhibit Tdp1 at concentrations of
0.16–2 µM. In vitro experiments with cell cultures confirmed that they show a synergistic effect with
Top1 inhibitors, leading to an order of a magnitude increase in the cytotoxic effect of the antitumor drug
topotecan [18]. In vivo experiments have shown that Tdp1 inhibitor 9b reduces metastasis growth in
Lewis lung carcinoma models [20]. Derivatives of usnic acid containing arylidenehydrazinothiazole
substituent (10) are also very potent inhibitors of Tdp1 (IC50 values of 0.026–0.457 µM) [19]. The acute
toxicity of compounds of the class of hydrazinothiazole usnic acid derivatives was previously assessed
by us in [19], where numerous animal experiments confirmed not only the safety of the doses of the
inhibitor used in anticancer therapy, but also the absence of any increase in the general toxic effect
of topotecan in mice. It is also known that compound 10 (R = Br, Figure 3) has a LD50 of more than
5000 mg/kg [19]. The addition of para-bromobenzylidene substituent in the thiazole cycle (R = 4-Br)
enhanced the cytotoxic effect of topotecan during the combined action on the MCF-7 cell line.
Studies on a purified enzyme showed that the structure of the aryl substituent in hydrazinothiazole
derivatives of usnic acid significantly affects the inhibition potency of the compounds [19]. This study
was aimed at the synthesis of new hydrazinothiazole derivatives of usnic acid and their activity. As our
previous work using computer simulation [19] showed that the arylidenehydrazinothiazole fragment
entered the hydrophilic pocket of the enzyme, we therefore reasoned that the replacement of the
arylidene fragment with heteroarylidene and the introduction of extended substituents would enhance
their efficacy. The presence of a heteroatom in the aromatic system can contribute to greater affinity
with the hydrophilic pocket, and the introduction of additional substituents through the linker with
heteroatoms can also increase the binding specificity.
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In order to identify the structure–activity relationship, the synthesis and screening of new
hydrazinothiazole derivatives of usnic acid with varying substituent structures in the hydrazone
moiety of the molecule was conducted. The heterocycle size, type of heteroatom, position, and size of
various substituents were chosen as the variable parameters. In addition, pairs of enantiomers based
on natural (+) - and (−) usnic acids were synthesized to study the effect of the chiral center in the
dibenzofuran core for these compounds for the first time.
2. Results and Discussion
2.1. Chemistry
Compounds 16a–r and 17a–k were synthesized by a method similar to that developed
previously [19].
Thiosemicarbazones 13a–g and 13i–q were obtained using a known procedure [26].
Thiosemicarbazones 13h,r and 14a–k were obtained using the reaction of aldehydes (11h,r and 12a–k)
with thiosemicarbazide in ethanol (Scheme 1). The precipitate formed was filtered off, washed with
water, and then air dried. Thiosemicarbazones 13h,r and 14a–k were obtained with yields ranging
from 60% to 93%.
R-(+)-usnic acid ((+)-1) and S-(−)-usnic acid ((−)-1) were obtained by extraction from a mixture of
the lichen genus Usnea and Cladonia stellaris and used as the starting material [27]. The synthesis of
the bromo-substituted derivative 15 was performed by a reaction with bromine in dioxane [28]. New
derivatives of usnic acid hydrazonothiazoles 16a–r and 17a–k were synthesized by the reaction of the
bromo-substituted derivative 15 with thiosemicarbazones 13a–r and 14a–k in methanol. The precipitate
was filtered off, dissolved in methylene chloride, washed with sodium bicarbonate solution, and the
organic phase was evaporated (Scheme 1). Thus, usnic acid derivatives 16a–r and 17a–k were obtained
with yields from 20% to 97%.
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2.2. Biology
2.2.1. Structure–Activity Relationship Analysis
We first studied the inhibition potency of our compounds to Tdp1 by using a real-time
oligonucleotide biosensor assay that we have previously developed [9]. The assay was based
on the ability of Tdp1 to remove the fluorescence quencher from the 3’-end of DNA. The substrate is a
16-mer single-stranded oligonucleotide containing both a 5’-FAM fluorophore and a 3’-BHQ1 quencher.
The testing results are presented in Tables 1 and 2.
Table 1. The results from the biochemical and biophysical binding assays for ligands 16a–r.
The inhibition concentration at 50% (IC50) is given as well as the dissociation constant (KD).
Code Compound, R
(+)-enantiomer (−)-enantiomer
IC50/nM KD/µM IC50/nM KD/µM
16a
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The testing results are presented in Tables 1 an  2. 
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52 ± 18 n.d. 169 ± 6 281 ± 25
16h
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16m 
 
188 ± 3 n.d. 18 ± 1 354 ± 40 
16n 
 
151 ± 14 719 ± 17 29 ± 9 n.d. 
16o 
 
1690 ± 890 38 ± 2 570 ± 109 51 ± 4 
16p 
 
138 ± 3 268 ± 11 57 ± 1 n.d. 
16q 
 
21 ± 6 n.d. 81 ± 20 58±4 
16r 
 
55 ± 8 113 ± 52 53 ± 3 n.d. 
*n.d. – not determined. 
An analysis of the data in Table 1 shows that although the replacement of the arylidene fragment 
with heteroarylidene did not lead to a significant increase in activity, most of the synthesized new 
compounds were highly active Tdp1 inhibitors, with active concentrations between 20–200 nM, with 
the exception of 16b, 16c, and 16o. The size of the heterocyclic fragment and the nature of the 
heteroatom did not significantly affect the inhibitory activity. The formation of hydrobromide in the 
case of compounds 16a–c and 16o led to a decrease in inhibitory activity. The presence of a bromine 
atom (16f,h) or bulky aromatic fragment as a substituent in the heterocycle (16r) led to an increase in 
inhibitory activity. The most active compounds from this set contained pyrrole (16m) or the N-
methylpyrrole substituent (16n) in the hydrazone fragment of the (−)-enantiomer. A comparison of 
the data on the inhibitory activity of pairs of enantiomers did not allow us to reliably judge the role 
of the configuration of the optical center in the binding of the compound to the enzyme. For seven 
pairs of compounds, the inhibitory concentration was comparable (it was considered comparable if 
the concentration of one of the pairs was no more than two times the concentration of the other). For 
five pairs of compounds, a higher activity was observed for the (+)-enantiomers, while in other cases, 
(−)-enantiomers were more active.  
The following series of compounds was synthesized from benzaldehydes with an extended 
substituent.  
18 ± 3 n.d. 18 ± 1 354 ± 40
16n
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pairs of compounds, the inhibitory co centration was co parable (it was considered comparabl if the
concentration of one of the airs was no more than two tim s the concentration of the o her). F r five
Molecules 2019, 24, 3711 7 of 34
pairs of compounds, a higher activity was observed for the (+)-enantiomers, while in other cases,
(−)-enantiomers were more active.
The following series of compounds was synthesized from benzaldehydes with an extended substituent.
Table 2. The results from the biochemical and biophysical binding assays for ligands 17a–k.
The inhibition concentration at 50% (IC50) is given as well as the dissociation constant (KD).
Code R
(+)-enantiomer (−)-enantiomer
IC50/nM KD/µM IC50/nM KD/µM
17a
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Code R 
(+)-enantiomer (−)-enantiomer 
IC50/nM KD/µM IC50/nM KD/µM 
17a 
 
26 ± 8 212 ± 25 54 ± 3 n.d.* 
17b 
 
26 ± 4 131 ± 15 78 ± 3 n.d. 
17c 
 
41 ± 7 204 ± 23 37 ± 10 74 ± 4 
17d 
 
77 ± 3 130 ± 29 18 ± 1 76 ± 5 
17e 
 
64 ± 6 213 ± 4 30 ± 11 130 ± 8 
17f 
 
60 ± 1 127 ± 14 21 ± 5 536 ± 90 
17g 
 
122 ± 25 223 ± 42 94 ± 20 n.d. 
17h 
 
74 ± 1 188 ± 22 48 ± 2 n.d. 
17i 
 
80 ± 7 161 ± 22 59 ± 5 n.d. 
17j 
 
69 ± 14 69 ± 14 71 ± 15 n.d. 
26 ± 8 212 ± 25 4 ± 3 n.d.*
17b
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60 ± 1 127 ± 14 21 ± 5 536 ± 90 
17g 
 
122 ± 25 223 ± 42 94 ± 20 n.d. 
17h 
 
74 ± 1 188 ± 22 48 ± 2 n.d. 
17i 
 
80 ± 7 161 ± 22 59 ± 5 n.d. 
17j 
 
69 ± 14 69 ± 14 71 ± 15 n.d. 
64 ± 6 213 ± 4 30 ± 11 130 ± 8
17f
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17k 
 
54 ± 8 156 ± 8 46 ± 5 142 ± 11 
*n.d. – not determined. 
In general, we can say that the increase in the size of the substituent led to very good inhibitory 
activity in the concentration range of 18–122 nM. The presence of a halogen atom as a substituent in 
the terminal aromatic ring, as a rule, increases the inhibitory activity of the compounds. At the same 
time, the location and nature of the halogen atom as well as the number of halogen atoms in the 
terminal aromatic ring did not significantly affect the level of inhibitory activity. Replacing the O-/S- 
methylene linker (17a–h) with a piperazinemethylene linker (17i, 17j) also did not have significant 
effect. As the configuration of the optical center of the core of usnic acid is not of fundamental 
importance, we can only note a slight tendency to increase the inhibitory activity of (−)-enantiomers 
for compounds containing a chlorine atom in the terminal aromatic ring (17d,f,h). 
The binding of the synthesized compounds to recombinant Tdp1 was also tested (Tables 1 and 
2) by using an intrinsic tryptophan fluorescence quenching assay [29]. All of the tested compounds 
were found to bind to Tdp1, confirming the inhibition assays that the compounds are targeting Tdp1. 
Interestingly, the binding constant values (KD) of the compounds were all found to be in the mid-μM 
region. The discrepancy between the binding and inhibition assays may be due to the large substrate 
binding site that Tdp1 possesses, which contains both a DNA binding pocket and a peptide binding 
pocket as well as the active site. As our compounds are aromatic in nature, there is a possibility that 
they may bind to both the active site as well as non-specifically to the DNA/peptide binding pockets. 
Nonetheless, our results confirmed that the compounds were indeed binders of Tdp1, thus 
complementing our inhibition data. 
2.2.2. Synergistic Effect 
Top1 poisons are used as anticancer drugs for the treatment of a wide range of oncological 
diseases [30,31]. Since Tdp1 is involved in the removal of DNA damage caused by Top1 poisons, it is 
believed that Tdp1 is responsible for the drug resistance of some cancers [32]. Thus, a combination of 
Top1 poisons and Tdp1 inhibitors could improve the effectiveness of chemotherapy. 
First, we studied the intrinsic cytotoxicity of the compounds against HeLa cells (cervical 
carcinoma). For experiments on cells, we selected compounds which combined high inhibitory 
activity with good chemical accessibility. The MTT test data are shown in Figure 4 for compounds 
from both the heteroarylidene-hydrazinotiazole and arylidene-hydrazinotiazole subclasses. The 
arylidene-hydrazinothiazole usnic acid derivatives have low toxicity (Figure 4). Heteroarylidene-
hydrazinothiazole derivatives (+)- and (−)-16f, containing a bromothiophene residue, also have low 
toxicity (CC50 about 80 µM), while the 16d pair, containing a nitro group that is a known toxicophore 
[33], suppressed cell growth at a concentration of 20 µM. Based on these data, a 5 µM concentration 
of Tdp1 inhibitors was chosen for the next experiment. 
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linker (17a–h) with a pip razinemethylene linker (17i, 17j) also did not have significant effect. As the
configuration of the opti al center of the cor of usnic acid is not of fundamental importance, we ca
only note a slight t nden y t increase the inhibitory activity of (−)- nantiomers for compounds
containing a hlorine atom i the terminal aromatic ri g (17d,f,h).
The binding of the synthesized compounds to recombinant Tdp1 was also tested (Tables 1 and 2)
by using an intrinsic tryptophan fluoresce ce quen hing assay [29]. All of the tested compounds
were found to bind to Tdp1, confirming the inhibition assays that t e comp unds are targeting
Tdp1. Inter stingly, the binding constant values (KD the compounds were all found to be in
the mid-µM region. The discrepancy b tween the bindi g and inhibition assays may be due to th
large substrate binding site that Tdp1 po sesses, which contains both a DNA binding pocket and a
peptide binding pock t as well s th active ite. As our compounds are aromatic in natu , there i a
possibility that they may bind to both th active site as well as non-specifically to the DNA/peptide
binding pockets. Nonetheless, o r results confirmed hat the compounds inde d binders of Tdp1,
thus comple enting our inhibition data.
2.2.2. Synergistic Effect
Top1 poisons are used as anticancer drugs for the treatment of a wide range of oncological
diseases [30,31]. Since Tdp1 is involved in the removal of DNA damage caused by Top1 poisons, it is
believed that Tdp1 is responsible for the drug resistance of some cancers [32]. Thus, a combination of
Top1 poisons and Tdp1 inhibitors could improve the effectiveness of chemotherapy.
First, we studied the intrinsic cytotoxicity of the compounds against HeLa cells (cervical carcinoma).
For experiments on cells, we selected compounds which combined high inhibitory activity with
good chemical accessibility. The MTT test data are shown in Figure 4 for compounds from both
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the heteroarylidene-hydrazinotiazole and arylidene-hydrazinotiazole subclasses. The arylidene-
hydrazinothiazole usnic acid derivatives have low toxicity (Figure 4). Heteroarylidene- hydrazinothiazole
derivatives (+)- and (−)-16f, containing a bromothiophene residue, also have low toxicity (CC50 about
80 µM), while the 16d pair, containing a nitro group that is a known toxicophore [33], suppressed cell
growth at a concentration of 20 µM. Based on these data, a 5 µM concentration of Tdp1 inhibitors was
chosen for the next experiment.M lecules 2019, 24, 3711 9 of 34 
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Figure 4. The cytotoxicity of the hydrazinothiazole derivatives according to the MTT test. 
Since the ligands are intended for an adjuvant therapy, their own low toxicity and the absence 
of additional side effects are essential. Thus, with the exception of a few compounds, usnic acid 
hydrazinotiazole derivatives have low cytotoxicity and are suitable for further research. 
Next, we studied the effect of Tdp1 inhibitors on the cytotoxicity effect of topotecan, the Top1 
poison used in clinical settings. We used non-toxic concentrations of usnic acid derivatives (5 µM) 
and different concentrations of topotecan. The Tdp1 inhibitors increased the cytotoxic effect of 
topotecan approximately two to threefold (Figure 5) and the CC50 values decreased from 6 μM to 2–
3 μM. The sensitizing effect of the compounds did not depend on the structure of the substituent in 
the hydrazinothiazole moiety. 
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Figure 5. Dose-dependent action of topotecan (Tpc) in combination with usnic acid derivatives on 
HeLa cell viability using the MTT method. 
In order to derive the optimal concentration for the inhibitors to provide the maximum 
sensitizing effect, but remaining non-toxic, the concentrations with topotecan at 2 µM, were varied. 
Topotecan increased the cytotoxicity of the ligands dramatically from >70 µM to 5–10 µM (Figure 6).  
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Since the ligands are intended for an adjuvant therapy, their own low toxicity and the absence
of additional side effects are essential. Thus, with t e exception of a fe compounds, usnic acid
hydrazinotiazole derivatives have low cytotoxicity and are suitable for further research.
Next, we studied the effect of Tdp1 inhibitors o the cytotoxicity effect of topotecan, the Top1
poison used in clinical settings. We used non-toxic concentrations of usnic acid derivatives (5 µM) and
different concentrations of topotecan. The Tdp1 inhibitors increased the cytotoxic effect of topotecan
approximately two to threefold (Figure 5) and the CC50 values decreased from 6 µM to 2–3 µM.
The sensitizing effect of the compounds id not depe on the structure of the substituent in the
hydrazinothiazole moiety.
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In order to derive the optimal concentration for the inhibitors to provide the maximum sensitizing
effect, but remaining non-toxic, the concentrations with topotecan at 2 µM, were varied. Topotecan
increased the cytotoxicity of the ligands dramatically from >70 µM to 5–10 µM (Figure 6).
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Figure 6. Dose-dependent action of usnic acid derivatives in combination with topotecan (Tpc) on 
HeLa cell viability using the MTT method. 
We found the optimal compound concentrations of 20 µM. With topotecan at 2 µM, a 
pronounced cytotoxic effect was observed at this concentration for the ligands, while in the absence 
of topotecan, such concentrations were almost non-toxic.  
Since there is no information on the rate and efficiency of the penetration of compounds into the 
cells, we studied the effect of the order of administration of (+)-17b and topotecan on their synergistic 
effect. Figure 7A shows the dependence of cell survival on topotecan concentration at 20 μM of (+)-
17b: topotecan and the Tdp1 inhibitor were applied to the wells simultaneously, pre-mixed (red 
graph); first topotecan, then after 30 minutes (+)-17b (blue graph); first (+)-17b, after 30 minutes 
topotecan (pink graph). The data showed that the simultaneous administration of drugs reduced the 
synergistic effect and that the sequence of separately administrating the drugs did not have an effect.  
When varying the concentration of (+)-17b with 2 µM of topotecan, the administration of (+)-17b 
after topotecan (pink graph, Figure 7B) led to worse results when compared with simultaneous 
administration (red graph) and even more so when compared with the administration first with the 
Tdp1 inhibitor, and then the Top1 inhibitor (blue graph). 
It is likely that a more pronounced effect occurs when first suppressing the ability of cells for 
repair, and subsequently causes damage. Apparently, the administration of topotecan first gives cells 
time to repair part of the DNA damage.  
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Figure 7. Dose-dependent action of (A) 2 µM topotecan in combination with 20 µM (+)-17b and (B) 
20 µM (+)-17b in combination with 2 µM topotecan (Tpc) on HeLa cell viability using the MTT 
method. 
Figure 6. Dose-dependent action of usnic acid derivatives in combination with topotecan (Tpc) on
HeLa cell viability using the MTT method.
We found the optimal compound concentrations of 20 µM. With topotecan at 2 µM, a pronounced
cytotoxic effect was observed at this co centratio for the ligands, while in the absence of topotecan,
such concentrations were almo t non-toxic.
Since there is no information on the rate and efficiency of the penetration of compounds into the
cells, we studied the effect of the order of administration of (+)-17b and topotecan on their synergistic
effect. Figure 7A shows the dependence of cell survival on topotecan concentration at 20 µM of (+)-17b:
topotecan and the Tdp1 inhibitor were applied to the wells simultaneously, pre-mixed (red graph);
first topotecan, then after 30 minutes (+)-17b (blue graph); first (+)-17b, after 30 minutes topotecan
(pink graph). The data showed that the simultaneous administration of drugs reduced the synergistic
effect and that the sequence of separately administrating the drugs did not have an effect.
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Figure 7. Dose-dependent action of (A) 2 µM topotecan in combination with 20 µM (+)-17b and (B) 
20 µM (+)-17b in combination with 2 µM topotecan (Tpc) on HeLa cell viability using the MTT 
method. 
Figure 7. se- ependent action of (A) 2 µM topotecan in combinatio with 20 µM (+)-17b and (B)
20 µM (+)-17b in combination with 2 µM topotecan (Tpc) on eLa cell viability using the MTT method.
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When varying the concentration of (+)-17b with 2 µM of topotecan, the administration of (+)-17b
after topotecan (pink graph, Figure 7B) led to worse results when compared with simultaneous
administration (red graph) and even more so when compared with the administration first with the
Tdp1 inhibitor, and then the Top1 inhibitor (blue graph).
It is likely that a more pronounced effect occurs when first suppressing the ability of cells for
repair, and subsequently causes damage. Apparently, the administration of topotecan first gives cells
time to repair part of the DNA damage.
2.3. Molecular Modeling
The fifty-eight molecules (16a–r, 17a–k) were docked into the binding site of Tdp1 (PDB ID: 6DIE,
resolution 1.78 Å) [34] both with and without water molecules (see further details in the Methodology
section). The co-crystallized ligand benzene-1, 2, 4-tricarboxylic acid was removed, re-docked, and
compared with the co-crystallized structure. The Astex statistical potential (ASP) scoring function
obtained an average root-mean-square deviation (RMSD) of 2.896 Å, improved piecewise linear
potential (ChemPLP) of 2.818 Å, a ChemScore (CS) of 0.613 Å, and a GoldScore (GS) of 9.596 Å when
docked with the crystalline water molecules. Meanwhile, ASP obtained an average RMSD of 2.868 Å,
ChemPLP of 4.422 Å, CS of 4.557 Å, and GS of 4.024 Å when docked without the water molecules (see
Table S17 in the Supplementary Materials). Docking with the water molecules obtained higher scores
than without water (see Table S18 in the Supplementary Materials). Better results were obtained when
keeping the crystalline water molecules in the docking scaffold. The new 6DIE holo-crystal structure
now allows for more robust modeling of TDP1 inhibitors when compared to prior apo-structures.
When the scores, with and without the crystalline water, were correlated to both the IC50 and KD values,
a weak trend was seen with R2 values in the range of ~0.1. However, in all cases, the slope of the fitted
line had a negative value (i.e., higher scores resulted in ligands that are more potent in general).
The modeling showed that all of the ligands had a plausible binding mode. Considering (+)-17b,
the most active molecule, the dibenzofuran and the thiazole moieties occupy the hydrophilic binding
region, which contains amino acids such as glutamic acid and threonine, whilst the anisole and the
fluorobenzene group occupy the hydrophobic region with amino acids such as isoleucine, leucine,
and phenylalanine. The carbonyl on the dibenzofuran moiety forms a hydrogen bond with the side
chain hydroxyl group of threonine (Thr261). A phenyl group on this moiety also forms a hydrogen
bond with the side chain amine group of asparagine (Asn516). The fluoride group of this molecule
also interacts with the side chain amine of glutamine (Gln241) and the imidazole group of histidine
(His237). The imidazole groups of the catalytic histidine amino acid residues His263 and His 493 are
blocked by the ligands, explaining the effective inhibition of Tdp1 [10,13–15,35]. The co-crystalized
ligand benzene-1,2,4-tricarboxylic acid forms hydrogen bonds with His493 and blocks access to His263,
explaining its efficacy. It also forms hydrogen bonds with Lys265, Ser399, and Lys495, which were not
seen for (+)-17b. This further strengthens the argument that blocking access to the His263/493 catalytic
pair is paramount in developing effective Tdp1 inhibitors. The binding of (+)-17b is shown in Figure 8.
Interestingly, very similar scores were predicted for both the enantiomers, reflecting the findings from
the activity and affinity experiments (i.e., the binding pocket can accommodate both forms).
2.4. Chemical Space
In order to check the compatibility of the ligands with biological systems, their physicochemical
parameters were derived. The calculated molecular descriptors (MW (molecular weight), log P
(water–octanol partition coefficient), HD (hydrogen bond donors), HA (hydrogen bond acceptors), PSA
(polar surface area), and RB (rotatable bonds)) are given in Table S19 in the Supplementary Materials.
MW, HA, PSA, and RB were within the drug-like and known drug space. The log P values ranged from
lead-like to just beyond the known drug space, while HD was within the lead-like space. The lead-like
chemical space is defined as relatively small parameters based on lead compounds, which can be
developed further and gain both weight and lipophilicity. The drug-like chemical space is based on
Molecules 2019, 24, 3711 12 of 34
orally bioavailable drug candidates, and finally, the known drug space (KDS) encompasses all small
molecules in clinical use (for further discussion and use of these regions in chemical space see [36]
and Table S20). The molecular weight of the ligands was between 492.5 and 752.8 g mol−1 and the log
P values were in the range of 1.5 and 7.1, which was just beyond the KDS region. The ligands had
PSA values between 132.5 and 198.3, reaching beyond the KDS. Therefore, it can be concluded that the
ligands were relatively large and upon further development, could not be made much larger.
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2.3. Molecular Modeling 
The fifty-eight molecules (16a–r, 17a–k) were docked into the binding site of Tdp1 (PDB ID: 
6DIE, resolution 1.78 Å ) [34] both with and without water molecules (see further details in the 
Methodology section). The co-crystallized ligand benzene-1, 2, 4-tricarboxylic acid was removed, re-
docked, and compared with the co-crystallized structure. The Astex statistical potential (ASP) scoring 
function obtained an average root-mean-square deviation (RMSD) of 2.896 Å , improved piecewise 
linear potential (ChemPLP) of 2.818 Å , a ChemScore (CS) of 0.613 Å , and a GoldScore (GS) of 9.596 Å  
when docked with the crystalline water molecules. Meanwhile, ASP obtained an average RMSD of 
2.868 Å , ChemPLP of 4.422 Å , CS of 4.557 Å , and GS of 4.024 Å  when docked without the water 
molecules (see Table S17 in the Supplementary Materials). Docking with the water molecules 
obtained higher scores than without water (see Table S18 in the Supplementary Materials). Better 
results were obtained when keeping the crystalline water molecules in the docking scaffold. The new 
6DIE holo-crystal structure now allows for more robust modeling of TDP1 inhibitors when compared 
to prior apo-structures. When the scores, with and without the crystalline water, were correlated to 
both the IC50 and KD values, a weak trend was seen with R2 values in the range of ~0.1. However, in 
all cases, the slope of the fitted line had a negative value (i.e., higher scores resulted in ligands that 
are more potent in general). 
The modeling showed that all of the ligands had a plausible binding mode. Considering (+)-17b, 
the most active molecule, the dibenzofuran and the thiazole moieties occupy the hydrophilic binding 
region, which contains amino acids such as glutamic acid and threonine, whilst the anisole and the 
fluorobenzene group occupy the hydrophobic region with amino acids such as isoleucine, leucine, 
and phenylalanine. The carbonyl on the dibenzofuran moiety forms a hydrogen bond with the side 
chain hydroxyl group of threonine (Thr261). A phenyl group on this moiety also forms a hydrogen 
bond with the side chain amine group of asparagine (Asn516). The fluoride group of this molecule 
also interacts with the side chain amine of glutamine (Gln241) and the imidazole group of histidine 
(His237). The imidazole groups of the catalytic histidine amino acid residues His263 and His 493 are 
blocked by the ligands, explaining the effective inhibition of Tdp1 [10,13–15,35]. The co-crystalized 
ligand benzene-1,2,4-tricarboxylic acid forms hydrogen bonds with His493 and blocks access to 
His263, explaining its fficacy. It also forms hydrogen bonds with Lys265, Ser399, and Lys495, which 
were not seen for (+)-17b. This further strengthens the argument that blocking access to the 
His263/493 catalytic pair is paramount in developing effective Tdp1 inhibitors. The binding of (+)-
17b is shown in Figure 8. Interestingly, very similar scores were predicted for both the enantiomers, 
reflecting the findings from the activity and affinity experiments (i.e., the binding pocket can 
accommodate both forms).  
 
 
 
(A) (B) 
Figure 8. The docked configuration of (+)-17b in the binding site of Tdp1 as predicted using the 
ChemScore scoring function. (A) The protein surface is rendered. The ligand occupies the binding 
pocket. Blue depicts a hydrophilic region on the surface; brown depicts hydrophobic region and 
Figure 8. The docked configuration of (+)-17b in the binding site of Tdp1 as predicted using the
ChemScore scoring function. ( ) rotein surface is rendered. The ligand occupies the binding
pocket. Blue depicts a hydr i region on the surface; brown depicts hydrophob c region and
whites shows neutral areas. (B) Hydrogen bonds are shown as green lines between Thr261, Asn516.
The fluoride moiety interacts with Gln241 and His237. The water molecules also form hydrogen bonds
with Ser459, Ser514, and Lys495.
To gauge the balance of the molecular descriptors of the ligands and therefore their compatibility
with biological systems, the known drug index (KDI) was calculated. This method is based on the
statistical analysis of drugs in clinical use (KDS) and the weighted indexes for each of the six descriptors
used. Both the summation (KDI2a) and multiplication (KDI2b) methods were used [37]. KDI2a is more
forgiving than its KDI2a counterpart, since a poor index for one parameter can be compensated for,
but when multiplied will result in a poor score as the multiplication of small numbers will lead to
small numbers. The KDI2a values ranged from 2.4 to 5.5 with a theoretical maximum of 6 and the
average of 4.08 for known drugs. KDI2b ranged from 0.0 to 0.57, with a theoretical maximum of 1
and with a KDS average of 0.18. This indicates that some of the ligands were relatively well balanced.
The most potent ligand (+)-17b had a KDI2a of 3.41 and KDI2b of 0.01; the balance of the molecular
descriptors is relatively good compared to known drugs with the exception of MW (657.7 g mol−1),
which resulted in a very low number for KDI2b, but a good value for KDI2a.
3. Materials and Methods
3.1. Chemistry
The analytical and spectral studies were conducted at the Chemical Service Center for the collective
use of Siberian Branch of the Russian Academy of Science.
The 1H and 13C-NMR spectra for solutions of the compounds in CDCl3 were recorded on a Bruker
AV-400 spectrometer (400.13 and 100.61 MHz, respectively). The residual signals of the solvent were
used as references (δH 2.48, δC 39.52 for DMSO-d6 and δH 7.27, δC 77.1 for CDCl3). The mass spectra
(70 eV) were recorded on a DFS Thermo Scientific high-resolution mass spectrometer. The melting
points were measured using a Kofler heating stage. The specific rotation was determined on a
PolAAr 3005 (Optical Activity Ltd, England) and provided in (deg × mL) × (g × dm)–1, whereas the
concentration of the solutions is shown in g × (100 × mL)–1. Merck silica gel (63–200 µ) was used for
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the column chromatography. Thin-layer chromatography was performed on TLC Silica gel 60F254
(Merck KGaA, Darmstadt, Germany).
The atom numbers in the compound are provided for the assignment of signals in the NMR spectra
and are different from the numeration in the nomenclature name. The target compounds reported
in this manuscript had a purity of at least 99% (HPLC). All chemicals were used as described unless
otherwise noted. Reagent-grade solvents were redistilled prior to use. Synthetic starting materials,
reagents, and solvents were purchased from Sigma-Aldrich, Acros Organics, and AlfaAesar.
(R)-(+)-Usnic acid 1 (αD +478 (c 0.1, CHCl3)) was isolated from a mixture of lichens of the genus
Usnea through the procedure developed by Salakhutdinov et al. [27]. (S)-(−)-Usnic acid 1 (αD −456
(c 0.1, CHCl3)) was isolated from Cladonia stellaris, by the same procedure [27].
Aldehydes 12a–k were obtained using a known procedure [38,39].
Compounds (+)-15 and (−)-15 were obtained using a known procedure. The spectra of the
substances coincided with that in the literature [28,40].
3.1.1. General Procedure for the Synthesis of Compounds 13a–r and 14a–k
A total of 1 mM of the corresponding aldehyde 11a–r and 12a–k was dissolved in 2 mL of ethyl
alcohol. The resulting solution was slowly added dropwise with stirring to a solution of 1 mM
thiosemicarbazide in 2 mL of distilled water. The precipitate that formed was filtered off, washed with
water, then air dried. The thiosemicarbazones 13a–r and 14a–k obtained were isolated in 58–93% yields.
(E)-2-(Pyridin-4-ylmethylene)hydrazinecarbothioamide (13a): Pale yellow solid with an 84% yield.
The spectrum of the substance corresponds to the literature [26].
(E)-2-(Pyridin-2-ylmethylene)hydrazinecarbothioamide (13b): Straw solid with a 65% yield. The spectrum
of the substance corresponds to the literature [41]
(E)-2-(Pyridin-2-ylmethylene)hydrazinecarbothioamide (13c): White solid with a 77% yield. The spectrum
of the substance corresponds to the literature [42].
(E)-2-((5-Nitrothiophen-2-yl)methylene)hydrazinecarbothioamide (13d): Yellow solid with a 76% yield.
The spectrum of the substance corresponds to the literature [43].
(E)-2-((5-Methylthiophen-2-yl)methylene)hydrazinecarbothioamide (13e): Yellow solid with a 92% yield.
The spectrum of the substance corresponds to the literature [43].
(E)-2-((5-Bromothiophen-2-yl)methylene)hydrazinecarbothioamide (13f): Straw solid with a 76% yield.
The spectrum of the substance corresponds to the literature [42].
(E)-2-(Thiophen-2-ylmethylene)hydrazinecarbothioamide (13g): Brown solid with an 89% yield.
The spectrum of the substance corresponds to the literature [44].
(E)-2-((4-Bromothiophen-2-yl)methylene)hydrazinecarbothioamide (13h): Straw solid with a 93% yield. NMR
1H (DMSO-d6, δ): 1.52 (1H, s, H-3), 7.67 (1H, bs, NH2), 7.74 (1H, s, H-1), 8.16 (1H, s, H-5), 8.24 (1H, bs,
NH2), 11.52 (1H, s, NH). SNMR 13C (DMSO-d6, δ): 109.33 (C-2), 125.95 (C-1), 131.55 (C-3), 135.81 (C-5),
140.08 (C-4), 177.82 (C-6).
(E)-2-((3-Methylthiophen-2-yl)methylene)hydrazinecarbothioamide (13i): Straw solid with an 84% yield.
The spectrum of the substance corresponds to the literature [45].
(E)-2-((Thiophen-3-yl)methylene)hydrazinecarbothioamide (13j): Straw solid with an 81% yield. The spectrum
of the substance corresponds to the literature [46].
(E)-2-(Furan-2-ylmethylene)hydrazinecarbothioamide (13k): Straw solid with a 60% yield. The spectrum of
the substance corresponds to the literature [42].
(E)-2-(Furan-3-ylmethylene)hydrazinecarbothioamide (13l): Brown solid with 5a 8% yield. The spectrum of
the substance corresponds to the literature [44].
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(E)-2-((1H-Pyrrol-2-yl)methylene)hydrazinecarbothioamide (13m): White solid with a 74% yield. The spectrum
of the substance corresponds to the literature [42].
(E)-2-((1-Methyl-1H-pyrrol-2-yl)methylene)hydrazinecarbothioamide (13n): Pale pink solid with a 63% yield.
The spectrum of the substance corresponds to the literature [47].
(E)-2-((1H-Imidazol-5-yl)methylene)hydrazinecarbothioamide (13o): White solid with a 74% yield.
The spectrum of the substance corresponds to the literature [48].
(E)-2-((1H-Indol-3-yl)methylene)hydrazinecarbothioamide (13p): Creamy solid with a 74% yield.
The spectrum of the substance corresponds to the literature [49].
((E)-2-((1H-2-Methylindol-3-yl)methylene)hydrazinecarbothioamide (13q): Straw solid with a 74% yield.
The spectrum of the substance corresponds to the literature [49].
(E)-2-((5-(3-Chlorophenyl)furan-2-yl)methylene)hydrazinecarbothioamide (13r): Yellow solid with a 90%
yield. NMR 1H (DMSO-d6, δ): 7.07 (1H, d, J = 3.57 Hz, AB-system, H-9), 7.23 (1H, d, J = 3.57 Hz,
AB-system, H-8), 7.37 (1H, m, H-Ar), 7.45 (1H, t, J = 7.84 Hz, H–Ar), 7.79 (1H, m, H-Ar), 7.89 (1H, t, J =
1.77 Hz, H-Ar), 7.85 (1H, bs, NH2), 7.89 (1H, m, H-2), 7.98 (1H, s, H-11), 8.29 (1H, bs, NH2), 11.53 (1H,
s, NH). NMR 13C (DMSO-d6, δ): 109.66 (C-9), 115.31 (C-8), 122.49 (C-Ar), 123.41 (C-Ar), 127.80 (C-Ar),
130.80 (C-Ar), 131.45 (C-1), 131.68 (C-11), 133.86 (C-3), 149.54 (C-10), 152.83 (C-7), 177.75 (C-12).
(E)-2-(3-((4-Fluorophenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothioamide (14a): White amorphous
powder with a 75% yield. NMR 1H (400 MHz, DMSO-d6): see Table 3. NMR 13C (100 MHz, DMSO-d6):
see Table 4.
(E)-2-(3-((3-Fluorophenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothioamide (14b): White amorphous
powder with a 71% yield. NMR 1H (400 MHz, DMSO-d6): see Table 3. NMR 13C (100 MHz, DMSO-d6):
see Table 4.
(E)-2-(3-((2-Fluorophenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothio amide (14c): White amorphous
powder with a 73% yield. NMR 1H (400 MHz, DMSO-d6): see Table 3. NMR 13C (100 MHz, DMSO-d6):
see Table 4.
(E)-2-(3-((3-Chloro-4-fluorophenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothio amide (14d): White
amorphous powder with a 60% yield. NMR 1H (400 MHz, DMSO-d6): see Table 3. NMR 13C (100 MHz,
DMSO-d6): see Table 4.
(E)-2-(3-((2,4-Difluorophenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothioamide (14e): White amorphous
powder with 68% yield. Spectra NMR 1H (400 MHz, DMSO-d6): Table 3. Spectra NMR 13C (100 MHz,
DMSO-d6): Table 4.
(E)-2-(3-((2-Chloro-4-fluorophenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothio amide (14f): White
amorphous powder with an 82% yield. NMR 1H (400 MHz, DMSO-d6): see Table 3. NMR 13C
(100 MHz, DMSO-d6): see Table 4.
(E)-2-(3-((2-tert-Butyl-5-methylphenylthio)methyl)-4-methoxybenzylidene)hydrazinecarbo thioamide (14g):
White amorphous powder with a 91% yield. NMR 1H (400 MHz, DMSO-d6): see Table 5. NMR 13C
(100 MHz, DMSO-d6): see Table 6.
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(2S)‐4‐Acetyl‐10‐{2‐[(E)‐2‐({3‐[(4‐chloro‐3‐methylphenoxy)methyl]‐4‐methoxyphenyl}methylidene)hydrazin‐
1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐
pentaen‐3‐one (-)-17h: Orange amorphous powder with a 51% yield.  
(2R)‐4‐Acetyl‐10‐{2‐[(E)‐2‐[(3‐{[4‐(4‐fluorophenyl)piperazin‐1‐yl]methyl}‐4‐
methoxyphenyl)methylidene]hydrazin‐1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐
oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐pentaen‐3‐one (+)-17i: Orange amorphous powder with a 
91% yield. M.p.: 175–179 °C dec. NMR 1H (400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, 
CDCl3): see Table 18. HRMS: m/z 725.2274 [M]+ (calcd. for (C38H36O7N5F1S1)+: 725.2314).  
(2S)‐4‐Acetyl‐10‐{2‐[(E)‐2‐[(3‐{[4‐(4‐fluorophenyl)piperazin‐1‐yl]methyl}‐4‐
methoxyphenyl)methylidene]hydrazin‐1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐
oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐pentaen‐3‐one (-)-17i: Orange amorphous powder with an 
85% yield.  
(2R)‐4‐Acetyl‐10‐{2‐[(E)‐2‐[(3‐{[4‐(2‐methoxyphenyl)piperazin‐1‐yl]methyl}‐4‐
methoxyphenyl)methylidene]hydrazin‐1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐
oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐pentaen‐3‐one (+)-17j: Orange amorphous powder with a 
50% yield. M.p.: 171–175 °C dec. NMR 1H (400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, 
CDCl3): see Table 18. HRMS: m/z 737.8204 [M]+ (calcd. for (C39H39O8N5S1)+: 737.8207).  
(2S)‐4‐Acetyl‐10‐{2‐[(E)‐2‐[(3‐{[4‐(2‐methoxyphenyl)piperazin‐1‐yl]methyl}‐4‐
methoxyphenyl)methylidene]hydrazin‐1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐
oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐pentaen‐3‐one (-)-17j: Orange amorphous powder with a 53% 
yield.  
(2R)‐4‐Acetyl‐10‐{2‐[(E)‐2‐({3‐[(3,5‐dimethyl‐4‐nitro‐1H‐pyrazol‐1‐yl)methyl]‐4‐
methoxyphenyl}methylidene)hydrazin‐1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐
oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐pentaen‐3‐one (+)-17k: Orange amorphous powder with an 
85% yield. M.p.: 160–165 °C dec. NMR 1H (400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, 
CDCl3): see Table 18. HRMS: m/z 686.1806 [M]+ (calcd. for (C33H30O9N632S1)+: 686.1790). 
(2S)‐4‐Acetyl‐10‐{2‐[(E)‐2‐({3‐[(3,5‐dimethyl‐4‐nitro‐1H‐pyrazol‐1‐yl)methyl]‐4‐
methoxyphenyl}methylidene)hydrazin‐1‐yl]‐1,3‐thiazol‐4‐yl}‐5,11,13‐trihydroxy‐2,12‐dimethyl‐8‐
oxatricyclo[7.4.0.02,7]trideca‐1(9),4,6,10,12‐pentaen‐3‐one (-)-17k: Orange amorphous powder with an 
87% yield. 
3.1.3. NMR Spectra of Compounds 14a–k, 16a–r, 17a–k. 
Table 3. NMR 1H spectra of 14a–14f (DMSO-d6, ). 
 
№ 14a 14b 14c 14d 14e 14f 
H-2 s 8.00 s 8.01 s 8.01 s 8.00 s 8.01 s 8.01 
H-5 m 7.00–7.15 m 7.08–7.30 
d 7.09 
(J = 8.7 Hz) 
d 7.07 
(J = 8.6 Hz) 
d 7.01 
(J = 8.6 Hz) 
d 7.01 
(J = 8.6 Hz) 
H-6 m 7.72 m 7.75 m 7.77 m 7.72 m 7.75 m 7.77 
H-7 s 3.86 s 3.86 s 3.85 s 3.85 s 3.86 s 3.86 
№ 14a 14b 14c 14d 14e 14f
H-2 s 8.00 s 8.01 s 8.01 s 8.00 s 8.01 s 8.01
H-5 m 7.00–7.15 m 7.08–7.30 d 7.09(J = 8.7 Hz)
d 7.07
(J = 8.6 Hz)
d 7.01
(J = 8.6 Hz)
d 7.01
(J = 8.6 Hz)
H-6 m 7.72 m 7.75 m 7.77 m 7.72 m 7.75 m 7.77
H-7 s 3.86 s 3.86 s 3.85 s 3.85 s 3.86 s 3.86
H-8 s 8.12 s 8.13 s 8.16 s 8.14 s 8.13 s 8.15
H-9 s 5.00 s 5.09 s 5.09 s 5.02 s 5.04 s 5.09
H-11 m 7.00–7.15 m 7.08–7.30 t 7.35(J = 9.1 Hz)
H-12 m 7.00–7.15 m 7.21 m 6.77 m 7.42
H-13 m 7.08–7.30 m 7.28
H-14 m 7.00–7.15 m 7.08–7.30 t 7.11(J = 7.7 Hz) m 7.27 m 6.77 m 7.28
H-15 m 7.00–7.15 m 6.95 m 6.95 m 7.02 m 6.77 m 7.17
NH s 11.32 s 11.33 s 11.35 s 11.34 s 11.33 s 11.33
NH2 m 7.90 m 7.89 m 7.90 m 7.92 m 7.93 m 7.87
Table 4. NMR 13C spectra of 14a–14f (DMSO-d6, δ).
№ 14a 14b 14c 14d 14e 14f
C-1 125.39 124.99 124.57 124.94 124.53 124.93
C-2 129.11 129.54 129.12 129.27 129.57 129.20
C-3 126.95 126.97 126.56 126.99 127.01 126.98
C-4 159.03 159.18 158.78 159.07 159.17 159.10
C-5 111.60 111.74 111.32 111.65 111.68 111.78
C-6 129.85 129.99 129.57 130.08 130.30 129.83
C-7 56.23 56.27 55.86 56.25 56.26 56.29
C-8 142.52 142.41 141.99 142.42 142.33 142.44
C-9 65.62 66.17 65.75 66.03 66.12 66.78
C-10 155.33 d 146.83(J = 10 Hz)
d 146.42
(J = 11 Hz)
d 155.62
(J = 2.4 Hz)
t 161.17
(J = 14 Hz)
d 151.14
(J = 2.4 Hz)
C-11 d 116.37(J = 4 Hz) 115.69
d 150.60
(J = 248 Hz)
d 115.53
(J = 7 Hz)
d 162.40
(J = 244 Hz)
d 122.50
(J = 10 Hz)
C-12 d 116.19(J = 11 Hz)
d151
(J = 244 Hz)
d 115.96
(J = 18 Hz)
d 120.08
(J = 17 Hz)
t 96.65
(J = 27 Hz)
d 117.51
(J = 28 Hz)
C-13 d 155.83(J = 240 Hz)
d 116.38
(J = 18 Hz)
d 121.21
(J = 7 Hz)
d 151.12
(J = 247 Hz)
d 162.25
(J = 244 Hz)
d 155.08
(J = 247 Hz)
C-14 d 116.19(J = 11 Hz)
d 125.30
(J = 3 Hz)
d 124.88
(J = 3 Hz)
d 117.56
(J = 22 Hz) m 99.15
d 115.01
(J = 21 Hz)
C-15 d 116.37(J = 4 Hz)
d 121.63
(J = 7 Hz) 115.27 116.63 m 99.43
d 115.54
(J = 9.4 Hz)
C-16 178.04 178.06 177.64 178.06 178.07 178.09
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H-8 s 8.12 s 8.13 s 8.16 s 8.14 s 8.13 s 8.15 
H-9 s 5.00 s 5.09 s 5.09 s 5.02 s 5.04 s 5.09 
H-11 m 7.00–7.15 m 7.08–7.30  
t 7.35 
(J = 9.1 Hz) 
  
H-12 m 7.00–7.15  m 7.21  m 6.77 m 7.42 
H-13  m 7.08–7.30 m 7.28    
H-14 m 7.00–7.15 m 7.08–7.30 
t 7.11 
(J = 7.7 Hz) 
m 7.27 m 6.77 m 7.28 
H-15 m 7.00–7.15 m 6.95 m 6.95 m 7.02 m 6.77 m 7.17 
NH s 11.32 s 11.33 s 11.35 s 11.34 s 11.33 s 11.33 
NH2 m 7.90 m 7.89 m 7.90 m 7.92 m 7.93 m 7.87 
Table 4. NMR 13C spectra of 14a–14f (DMSO-d6, ). 
№ 14a 14b 14c 14d 14e 14f 
C-1 125.39 124.99 124.57 124.94 124.53 124.93 
C-2 129.11 129.54 129.12 129.27 129.57 129.20 
C-3 126.95 126.97 126.56 126.99 127.01 126.98 
C-4 159.03 159.18 158.78 159.07 159.17 159.10 
C-5 111.60 111.74 111.32 111.65 111.68 111.78 
C-6 129.85 129.99 129.57 130.08 130.30 129.83 
C-7 56.23 56.27 55.86 56.25 56.26 56.29 
C-8 142.52 142.41 141.99 142.42 142.33 142.44 
C-9 65.62 66.17 65.75 66.03 66.12 66.78 
C-10 155.33 
d 146.83 (J = 10 
Hz) 
d 146.42 (J = 11 
Hz) 
d 155.62 (J = 2.4 
Hz) 
t 161.17 (J = 14 
Hz) 
d 151.14 (J = 
2.4 Hz) 
C-11 
d 116.37 (J = 4 
Hz) 
115.69 
d 150.60 (J = 
248 Hz) 
d 115.53 (J = 7 
Hz) 
d 162.40 (J = 
244 Hz) 
d 122.50 (J = 
10 Hz) 
C-12 
d 116.19 (J = 11 
Hz) 
d151 (J = 244 
Hz) 
d 115.96 (J = 18 
Hz) 
d 120.08 (J = 17 
Hz) 
t 96.65 (J = 27 
Hz) 
d 117.51 (J = 
28 Hz) 
C-13 
d 155.83 (J = 
240 Hz) 
d 116.38(J = 18 
Hz) 
d 121.21 (J = 7 
Hz) 
d 151.12 (J=247 
Hz) 
d 162.25 (J = 
244 Hz) 
d 155.08 
(J=247 Hz) 
C-14 
d 116.19 (J = 11 
Hz) 
d 125.30 (J = 3 
Hz) 
d 124.88 (J = 3 
Hz) 
d 117.56 (J = 22 
Hz) 
m 99.15 
d 115.01 (J=21 
Hz) 
C-15 
d 116.37 (J = 4 
Hz) 
d 121.63 (J = 7 
Hz) 
115.27 116.63 m 99.43 
d 115.54 (J = 
9.4 Hz) 
C-16 178.04 178.06 177.64 178.06 178.07 178.09 
Table 5. NMR 1H spectra of 14f–14k (DMSO-d6, ). 
 
№ 14g 14h 14i 14j 14k 
H-2 s 7.91 s 7.99 s 8.00 s 8.00 s 7.89 
H-5 
d 7.00 
(J = 9.3 Hz) 
m 7.04 m 7.02 d 7.05 (J = 8.5 Hz) 
d 7.03 
(J = 8.5 Hz) 
H-6 m 7.62 m 7.72 m 7.69 bs 7.75 m 7.63 
№ 14g 14h 14i 14j 14k
H-2 s 7.91 s 7.99 s 8.00 s 8.00 s 7.89
H-5 d 7.00(J = 9.3 Hz) m 7.04 m 7.02
d 7.05 (J = 8.5
Hz)
d 7.03
(J = 8.5 Hz)
H-6 m 7.62 m 7.72 m 7.69 bs 7.75 m 7.63
H-7 s 3.80 s 3.85 s 3.83 s 3.83 s 3.81
H-8 s 8.14 s 8.14 s 8.11 s 8.15 s 7.97
H-9 s 4.09 s 5.00 s 3.55 s 3.68 s 5.21
H-10 bs 2.57 bs 2.69
H-11 s 1.19 (t-Bu) bs 3.07 bs 2.93
H-12 s 7.09 s 2.28 (Me)
H-13 s 7.18 m 7.06 m 6.90 m 6.87–6.94 2.34
H-14 s 2.21 (Me) m 7.28 m 7.02 m 6.87–6.94 2.67
H-15 s 7.09 m 6.86 m 6.87–6.94
H-16 m 7.02 m 6.87–6.94
H-17 m 6.90 s 3.74 (OMe)
NH s 11.32 s 11.33 s 11.29 s 11.34 s 11.33
NH2 s 7.62 and s 7.80
s 7.89 and
s 7.93
m 7.69 and s
7.85
bs 7.72 and bs
7.90
s 7.75 and
s 7.78
(E)-2-(3-((4-Chloro-3-methylphenoxy)methyl)-4-methoxybenzylidene)hydrazinecarbothio amide (14h): White
amorphous powder with an 81% yield. NMR 1H (400 MHz, DMSO-d6): see Table 5. NMR 13C
(100 MHz, DMSO-d6): see Table 6.
(E)-2-(3-((4-(4-Fluorophenyl)piperazin-1-yl)methyl)-4-methoxybenzylidene)hydrazinecarbo thioamide (14i):
White amorphous powder with an 86% yield. NMR 1H (400 MHz, DMSO-d6): see Table 5. NMR 13C
(100 MHz, DMSO-d6): see Table 6.
(E)-2-(4-Methoxy-3-((4-(3-methoxyphenyl)piperazin-1-yl)methyl)benzylidene)hydrazine carbothioamide (14j):
White amorphous powder with a 74% yield. NMR 1H (400 MHz, DMSO-d6): see Table 5. NMR 13C
(100 MHz, DMSO-d6): see Table 6.
(E)-2-(3-((3,5-Dimethyl-4-nitro-1H-pyrazol-1-yl)methyl)-4-methoxybenzylidene)hydrazinecarbothioamide
(14k): White amorphous powder with a 69% yield. NMR 1H (400 MHz, DMSO-d6): see Table 5. NMR
13C (100 MHz, DMSO-d6): see Table 6.
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Table 6. NMR 13C spectra of 14f–14k (DMSO-d6, δ).
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H-7 s 3.80 s 3.85 s 3.83 s 3.83 s 3.81 
H-8 s 8.14 s 8.14 s 8.11 s 8.15 s 7.97 
H-9 s 4.09 s 5.00 s 3.55 s 3.68 s 5.21 
H-10   bs 2.57 bs 2.69  
H-11 s 1.19 (t-Bu)  bs 3.07 bs 2.93  
H-12 s 7.09 s 2.28 (Me)    
H-13 s 7.18 m 7.06 m 6.90 m 6.87-6.94 2.34 
H-14 s 2.21 (Me) m 7.28 m 7.02 m 6.87-6.94 2.67 
H-15 s 7.09 m 6.86  m 6.87-6.94  
H-16   m 7.02 m 6.87-6.94  
H-17   m 6.90 s 3.74 (OMe)  
NH s 11.32 s 11.33 s 11.29 s 11.34 s 11.33 
NH2 s 7.62 and s 7.80 
s 7.89 and 
s 7.93 
m 7.69 and s 7.85 bs 7.72 and bs 7.90 
s 7.75 and 
s 7.78 
Table 6. NMR 13C spectra of 14f–14k (DMSO-d6, ). 
№ 14g 14h 14i 14j 14k 
C-1 125.87 124.88 127.95 126.36 123.74 
C-2 129.13 129.36 126.19 128.64 129.05 
C-3 126.31 126.52 127.95 126.36 126.59 
C-4 158.47 158.57 159.03 159.28 158.26 
C-5 111.11 111.19 111.16 111.38 111.30 
C-6 129.59 129.50 129.64 130.46 129.37 
C-7 55.77 55.80 55.67 55.89 55.83 
C-8 142.02 142.12 142.24 142.42 141.87 
C-9 31.52 64.84 48.73 49.30 48.10 
C-10 134.24 157.29 55.06 55.05 145.04 
C-11 
148.8 (C, Ar) 
30.88 (Me t-Bu) 
34.14 (C, t-Bu) 
117.36 52.36 52.55 130.02 
C-12 128.25 
128.60 (C, Ar) 
19.79 (Me) 
147.75 152.02 141.38 
C-13 125.88 136.52 
117.02 
(J = 7 Hz) 
111.92 11.39 
C-14 
134.58 (C, Ar) 
19.32 (Me) 
124.70 
115.06 
(J = 22 Hz) 
118.13 13.90 
C-15 123.05 113.82 
d 155.00 
(J = 232 Hz) 
122.77  
C-16 177.58 177.66 
115.06 
(J = 22 Hz) 
120.92 177.67 
C-17   
117.02 
(J = 7 Hz) 
140.08  
C-18   177.60 177.64  
 
NMR 1Н (CDCl3, ): 1.67 (3H, s, H-15), 2.13 (3H, s, H-10), 2.61 (3H, s, H-12), 5.88 (1H, s, H-4). NMR 13С (CDCl3, 
): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.3 (C-9b), 97.2 (C-4), 97.3 (C-9a), 103.3 (C-6), 104.4 (C-14), 105.0 (C-2), 
№ 14g 14h 14i 14j 14k
C-1 125.87 124.88 127.95 126.36 123.74
C-2 129.13 129.36 126.19 128.64 129.05
C-3 126.31 126.52 127.95 126.36 126.59
C-4 158.47 158.57 159.03 159.28 158.26
C-5 111.11 111.19 111.16 111.38 111.30
C-6 129.59 129.50 129.64 130.46 129.37
C-7 55.77 55.80 55.67 55.89 55.83
C-8 142.02 142.12 142.24 142.42 141.87
C-9 31.52 64.84 48.73 49.30 48.10
C-10 134.24 157.29 55.06 55.05 145.04
C-11
148.8 (C, Ar)
30.88 (Me t-Bu)
34.14 (C, t-Bu)
117.36 52.36 52.55 130.02
C-12 128.25 128.60 (C, Ar)19.79 (Me) 147.75 152.02 141.38
C-13 125.88 136.52 117.02(J = 7 Hz) 111.92 11.39
C-14 134.58 (C, Ar)19.32 (Me) 124.70
115.06
(J = 22 Hz) 118.13 13.90
C-15 123.05 113.82 d 155.00(J = 232 Hz) 122.77
C-16 177.58 177.66 115.06(J = 22 Hz) 120.92 177.67
C-17 117.02(J = 7 Hz) 140.08
C-18 177.60 177.64
NMR 1H (CDCl3, δ): 1.67 (3H, s, H-15), 2.13 (3H, s, H-10), 2.61 (3H, s, H-12), 5.88 (1H, s, H-4). NMR 13C (CDCl3, δ):
8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.3 (C-9b), 97.2 (C-4), 97.3 (C-9a), 103.3 (C-6), 104.4 (C-14), 105.0 (C-2), 108.8
(C-8), 143.4 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 (C-1), 201.2
(C-11). NMR 1H (DMSO-d6, δ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.60 (3H, s, H-12), 6.20 (1H, s, H-4). NMR 13C
(DMSO-d6, δ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6
(C-14), 107.3 (C-8), 143.0 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9
(C-1), 201.2 (C-11).
3.1.2. General Procedure for the Synthesis of Compounds 16a–r and 17a–k
A mixture of compound (+)-15 or (−)-15 (1 mmol, 423 mg) and the corresponding thiosemicarbazone
13a–r or 14a–k (1 mmol) were heated under reflux in 25 mL MeOH for 0.5–2 h. The reaction mixture
was cooled and poured onto water (75 mL). After that, the reaction mixture was cooled, the precipitate
that formed was filtered off, washed with MeOH, and dried in air. The precipitate (except for 16a–c)
was placed in a separatory funnel, 30 mL of methylene chloride was added thereto, a suspension was
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formed, and 20 mL of a saturated solution of NaHCO3 was added. The mixture was shaken vigorously
several times until the suspension turned into a completely dark red solution. The resulting solution
was separated from the aqueous layer, washed with 20 mL water once, and evaporated on a rotary
evaporator. Compounds 16a–r and 17a–k obtained were isolated in 20–97% yields.
4-[(1E)-(2-{4-[(1R)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7]trideca-2(7),3,5,
9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]pyridin-1- ium bromide (+)-16a: Orange
amorphous powder with a 74% yield. M.p.: 191–193 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see
Table 7. NMR 13C (100 MHz, DMSO-d6): see Table 8. HRMS: m/z 504.1094 [M − HBr]+ (calcd.
for (C25H20O6N432S1)+: 504.1098). Anal. Calcd. for C25H21BrO6N4S1 (585.42): Br, 13.65%. Found:
Br, 13.58%.
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, δ).
№ 16a 16b 16c 16d 16e
Structure
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108.8 (C-8), 143.4 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 (C-1), 
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.60 (3H, s, H-12), 6.20 (1H, s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
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108.8 (C-8), 143.  (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.  (C-1), 
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.60 (3H, s, H-12), 6.20 (1H, s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 9.0 (C-9b), 96.  (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.  
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ).
№ 16a 16b 16c 16d 16e 
Struct re 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.2  s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.0  s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.7  bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.3  bs 10.3  s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ).
№ 16a 16b 16c 16d 16e 
Struct re 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130. 6 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.  126.7  149.84 142.34 
C-22 122.41 140.7  139.95  15.3  
Table 9. NMR1H spectra of 16f–16j (CD l3, ).
№ 16f 16g 16h 16i 16j 
Struct re 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.8  (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.2  (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.7  s 18.79 s 18.7  s 18.79 
Molecul s 2019, 24, 3711 23 of 34 
23 
 
108.8 (C-8), 143.  (C-13), 15 .3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.  (C-1), 
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, -15), 2.03 (3H, s, H-10), 2.6  (3H, s, H-12), 6.20 (1H, s, -4). NMR 13С 
(DMSO-d6, ): 8.  (C-10), 27.6 (C-12), 32.0 (C-15), 9.0 (C- b), 96.  (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 15 .3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.  
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Struct re 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.2  s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.0  s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.7  bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.3  bs 10.3  s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Struct re 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130. 6 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.  126.7  149.84 142.34 
C-22 122.41 140.7  139.95  15.3  
Table 9. NMR1H spectra of 16f–16j (CD l3, ). 
№ 16f 16g 16h 16i 16j 
Struct re 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.8  (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.2  (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.7  s 18.79 s 18.7  s 18.79 
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108.8 (C-8), 143.  (C- 3), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C- ), 180.4 (C-4a), 191.5 (C-3), 197.  (C- ),
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, -15), 2.03 ( H, s, -10), 2.6  (3H, s, -12), 6.20 (1H, s, -4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-1 ), 32.0 (C-15), 9.0 (C-9b), 96.  (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C- 3), 15 .3 (C-7), 51.4 (C-9), 56.3 (C-5a), 166.4 (C- ), 180.4 (C-4a), 191.5 (C-3), 97.  
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ).
№ 16a 16b 16c 16d 16e 
Struct re 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.2  s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.0  s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.7  bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.3  bs 10.3  s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ).
№ 16a 16b 16c 16d 16e 
Struct re 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130. 6 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.  126.7  149.84 142.34 
C-22 122.41 140.7  139.95  15.3  
Table 9. NMR1H spectra of 16f–16j (CD l3, ).
№ 16f 16g 16h 16i 16j 
Struct re 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.8  (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.2  (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.7  s 18.79 s 18.7  s 18.79 
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108.8 (C- ), 143.4 (C-13 5 7), 51.4 (C-9), 56.3 (C-5a 6 4 16 80 4a 91 5 3), 97.9 (C-1), 
201.  (C- 1). 
NMR 1Н (D SO-d6, ): 1.70 (3H s, H-15), 2.03 (3H s, H-10), 2.60 (3H s, H-12), 6.20 ( H s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C 10), 27.6 (C-12), 3 .0 (C-15), 59.0 (C- b), 6.9 (C-9a), 7.3 (C-4  10 .3 (C-6),105.  (C-2), 105.6 
(С-14), 07.3 C 8), 14 .0 (C-13 51 7), 151.4 (C-9), 156.3 (C-5a 6 4 16 80 4a 91 5 3), 197.9 
(C-1), 201.  (C- .
Table 7. NMR1H spectra of 16 –16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8 07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8 8  (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8 71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16 –16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137. 5 146.33 137.05 135.56 138.62 
C-18 148.81 150. 2 133.07 146.60 136.51 
C-19 122.41 124.8  141.66 130.58 130.36 
C-20 143. 6 138.72 143.08 128. 3 126.38 
C-21 143. 6 121.21 126.76 149.8  142.3  
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f– j (CD l3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = .9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16
H-19 d 8.10(J = 5.5 Hz)
d 8.07
(J = 8.0 Hz) s 9.13
d 7.34
(J = 4.5 Hz)
d 7.19
(J 4.9 Hz)
H-20 d 8.84(J = 5.5 Hz)
t 7.66
(J = 5.9 Hz)
d 8.85
(J = 5.1 Hz)
d 7.98
(J = 4.5 Hz) m 6.79
H-21 d 8.84(J = 5.5 Hz)
t 8.21
(J = 5.1 Hz) m 8.21
-22 d 8.10(J = 5.5 Hz)
d 8.71
(J = 5.1 Hz)
d 8.70
(J = 5.1 Hz) s 2.46
NH bs 12.37 bs 12.45 — s 12.78 —
OH 3 — 8 82 8.76 bs 18.78 bs 18.82
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27
OH-9 — bs 10.30 bs 10.30 s 10.23 s 10.27
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, δ).
№ 16a 16b 16c 16d 16e
Structure
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108.8 (C-8), 143.4 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 (C-1), 
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.60 (3H, s, H-12), 6.20 (1H, s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure
     
-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
0 
d 8. 4 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.2  s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structu e 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
Molecules 2019, 24, 3711 23 of 34 
23 
 
108.8 (C- ), 143.4 (C-13), 15 .3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 ( -16), 180.4 ( -4a), 191.5 ( -3), 197.9 (C-1), 
201.2 (C- 1). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.6  (3H, s, H-12), 6.20 (1H, s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C- b), 96.9 (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 15 .3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 
(C-1), 201.2 (C- 1). 
Table 7. NMR1H spectra of 16 –16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
   
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16 –16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = .9 Hz) 
-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
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108.8 (C- ), 143.4 ( -13 , 5 .  7), 151.4 (C-9), 156.3 (C-5a , 6 .4 16 , 80.  4a , 91.5 3), 197.9 (C-1), 
201.2 (C- 1). 
NMR 1Н (DMSO-d6, ): 1.70 (3H s, H-15), 2.03 (3 , s, H-10), 2.60 (3 , s, H-12), 6.20 (1 , s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C- b), 96.  (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 5 .  ( -7), 151.4 (C-9), 156.3 (C-5a), 6 .4 ( -16), 80.  ( -4a), 91.5 ( -3), 197.9 
(C-1), 201.2 (C- . 
Table 7. NMR1H spectra of 16 –16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.8  (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 2.9  s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16 –16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.21 12 .76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.0  (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = .9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
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108.8 (C- ), 143.4 ( -13), 51.3 (C-7), 51.4 ( -9), 6.3 ( -5a), 66.4 ( -16), 180.4 ( - a), 1 1.5 ( -3), 197.9 (C-1),
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2. 3 (3H, s, H-10), 2.60 (3H, s, H-12), 6. 0 (1H, s, H-4 . NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 2 , 32.0 5 , 59.  9b), 96.9 ( - a , 7.3 4), 103.  6 , 5.1 2 , .  
(С-14), 107.3 (C-8), 43.0 ( -1 ), 151.3 (C-7), .4 ( -9), 6.3 ( 5a), 1 6.4 (C-16), 180.4 (C- a), 191.5 (C-3), 7.9 
(C-1), 201.2 ( -11). 
Table 7. NMR1H spectra of 16a– e (DMSO-d6, ). 
№ 16a b c d 16e 
Structure 
     
H-14 s 7.39  . 8 27 s 7.23
H-17 s 8.16  . 5 22 08 s 8.16
H-19 
d 8.10 (J = 5.5 
Hz) 
.07 (J  8.0 
) 
s 9.13
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7 66 9
) 
d 8.85 (J = 5.1 7 98 4 5
m 6.79
H-21 
d 8.84 (J = 5.5 
Hz) 
t 21 1
) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
.71 (J  .1 
) 
0
 s 2.46
NH bs 12.37  .45 --- s 12.78 --- 
OH-3 --- bs 1 .82 76 8 bs 18.  
OH-7 s 13.28 s .05 2 96 49 s 12.27 
OH-9 --- bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a– e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137.15 46.33 137.05 135.56 138. 2 
C-18 148.81 150.12 133.07 146.60 13 .51 
C-19 122.41 124.82 141.66 30.58 130.36 
C-20 143.16 38.72 143.08 128.13 126. 8 
C-21 143.16 21.21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ).
№ 16f 16g 16h i 16j 
Structure 
     
H-14 s 7.1 s 7.08 s 7.04 s 7.09 s 7.12
H-17 s 7.58 s 7.81 b 8 12 s 7.73 s 7.78
H-19 d 6.77 (J = 3.8 Hz) d .08 (J = 3.4 Hz) s 7.04  s 7.43
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz)
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 4 (J = 4.9 Hz) m 7.31
H-22    s 2.23
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 1 .79 
Molecules 2019, 24, 371  23 of 34 
23 
 
108.8 (C-8), 143.4 (C- 3), 51.3 (C-7), 51.4 (C-9), 156.3 (C-5a), 166.4 (C- ), 80.4 (C-4a), 191.5 (C-3), 197.9 (C- ), 
201.  (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.60 ( H, s, H-1 ), 6.20 (1H, s, H-4)  NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-1 , 3 .0 (C-15), 59.0 (C-9b), 6.9 (C-9a), 7.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 07.3 (C-8), 3.0 (C- 3), 51.3 (C-7), 51.4 (C-9), 156.3 (C-5a), 66.4 (C-1 ), 80.4 (C-4a), 191.5 (C-3), 197.9 
(C-1), 201.  (C-11). 
Table 7. NMR1H spectr  of 16a– e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Struc ure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s .23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s .16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
 7.34 (J = 4.5 
z) 
d 7.19 (J = 4.9
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 ---
OH-3 - - bs 18.82 bs 18.76 bs 18.78 bs 1 .82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 - - bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a– e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Struc ure 
     
C-17 137. 5 146.33 137.05 135.56 138.62 
C-18 148.8  150. 2 133.07 146.60 136.51 
C-19 122.4  124.8  141.66 130.58 130. 6 
C-20 143. 6 138.72 143.08 128. 3 26.3  
C-21 143. 6 121.21 126.76 149.8  1 2.3  
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectr  of 16f– j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Struc ure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7. 8 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.0  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz)
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8. 9 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
C-17 137.15 146.33 137.05 135.56 138.62
C-18 48.81 150.12 133.07 146.60 136.51
C-19 22 41 24 8 1.66 58 130 6
C-20 143.16 138.72 143.08 128.13 126.38
C-21 143.16 121.21 126.76 149.84 142.34
C-22 122.41 140.70 139.95 15.35
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4-[(1E)-(2-{4-[(1S)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7] trideca-2(7),
3,5,9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]pyridin-1- ium bromide (−)-16a: Orange
amorphous powder with a 77% yield.
2-[(1E)-(2-{4-[(1R)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7] trideca-2(7),
3,5,9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]pyridin-1- ium bromide (+)-16b: Orange
amorphous powder with a 62% yield. M.p.: 189–192 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see
Table 7. NMR 13C (100 MHz, DMSO-d6): see Table 8. HRMS: m/z 504.1089 [M − HBr]+ (calcd. for
(C25H20O6N432S1)+: 504.1098). Anal. Calcd. for C25H21BrO6N4S1 (585.42): Br, 13.65%. Found:
Br, 13.59%.
2-[(1E)-(2-{4-[(1S)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo [7.4.0.02,7] trideca-2(7),
3,5,9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]pyridin-1- ium bromide (−)-16b: Orange
amorphous powder with a 63% yield.
3-[(1E)-(2-{4-[(1R)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7] trideca-2(7),
3,5,9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]pyridin-1- ium bromide (+)-16c: Orange
amorphous powder with a 58% yield. M.p.: 185–188 ◦C dec. NMR 1H (400 MHz, DMSO-d6):
Table 7. NMR 13C (100 MHz, DMSO-d6): see Table 8. HRMS: m/z 504.1104 [M − HBr]+ (calcd.
for (C25H20O6N432S1)+: 504.1098). Anal. Calcd. for C25H21BrO6N4S1 (585.42): Br, 13.65%. Found:
Br, 13.62%.
3-[(1E)-(2-{4-[(1S)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7]trideca-2(7),3,5,
9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]pyridin-1- ium bromide (−)-16c: Orange
amorphous powder with a 54% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(5-nitrothiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16d: Red amorphous
powder with a 74% yield. M.p.: 195–197 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see Table 7. NMR 13C
(100 MHz, DMSO-d6): see Table 8. HRMS: m/z 554.0555 [M]+ (calcd. for (C24H18O8N432S2)+: 554.0561).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(5-nitrothiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16d: Red amorphous
powder with a 75% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(5-methylthiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16e: Brown amorphous
powder with a 66% yield. M.p.: 165–167 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see Table 7. NMR 13C
(100 MHz, DMSO-d6): see Table 8. HRMS: m/z 523.0860 [M]+ (calcd. for (C25H21O6N3S2)+: 523.0866).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(5-methylthiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16e: Brown amorphous
powder with a 65% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(5-bromothiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16f : Brown amorphous
powder with a 75% yield. M.p.: 153–155 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 9. Spectra NMR
13C (100 MHz, CDCl3): see Table 10. HRMS: m/z 586.9820 [M]+ (calcd. for (C24H18O6N3BrS2)+: 586.9815).
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Table 9. NMR1H spectra of 16f–16j (CDCl3, δ).
№ 16f 16g 16h 16i 16j
Structure
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108.8 (C-8), 143.4 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 (C-1), 
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, H-15), 2.03 (3H, s, H-10), 2.60 (3H, s, H-12), 6.20 (1H, s, H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
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108.8 (C-8), 143.4 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 (C-1), 
201.2 (C-11). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s, -15), 2.03 (3H, s, -10), 2.6  (3H, s, -12), 6.20 (1H, s, -4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C-9a),97.3 (C-4), 103.3 (C-6),105.1 (C-2), 105.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 151.3 (C-7), 151.4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 191.5 (C-3), 197.9 
(C-1), 201.2 (C-11). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = .5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = .1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 121.21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = .9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79
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108.8 (C-8), 143.4 (C-1 ), 15 .3 (C-7), 15 .4 (C-9), 156.3 (C- a), 166.4 (C-1 ), 180.4 (C-4a), 19 .5 (C-3), 197.9 (C-1), 
201.2 (C-1 ). 
NMR 1Н (DMSO-d6, ): 1.70 (3H, s H-15), 2.03 (3H, s H-10), 2.60 (3H, s H-12), 6.20 (1H, s H-4). NMR 13С 
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C-9a), 7.3 (C-4), 103.3 (C-6),105.1 (C-2), 05.6 
(С-14), 107.3 (C-8), 143.0 (C-13), 15 .3 (C-7), 15 .4 (C-9), 156.3 (C-5a), 166.4 (C-16), 180.4 (C-4a), 19 .5 (C-3), 197.9 
(C-1), 201.2 (C-1 ). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = .  
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8.85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structure 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 14 .66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 143.16 12 .21 126.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.  Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz) 
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
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108.8 (C-8), 143.4 (C-13), 5 .3 (C-7), 15 .4 (C-9), 156.3 (C-5a), 166.4 (C-16), 80.4 (C-4a), 19 .5 (C-3), 197.9 (C-1), 
201.  (C-11). 
NMR 1Н (D SO-d6, ): 1.70 (3H, s H-15), 2.03 (3H, s H-10), 2.60 (3H, s H-12), 6.20 ( H, s H-4). NMR 13С
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 3 .0 (C-15), 59.0 (C-9b), 6.9 (C-9a),97.3 (C-4  10 .3 (C-6),105.  (C-2), 105.6 
(С-14), 07.3 (C-8), 14 .0 (C-13), 5 .3 (C-7), 15 .4 (C-9), 156.3 (C-5a), 166.4 (C-16), 80.4 (C-4a), 19 .5 (C-3), 197.9 
(C-1), 201.  (C-11). 
Table 7. NMR1H spectra of 16a– e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Struc ure 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s 7.23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s 8.16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8.07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = 4.5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = 5.9 
Hz) 
d 8 85 (J = 5.1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t 8.21 (J = 5.1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8.71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 18.82 
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27 
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27 
Table 8. NMR 13C spectra of 16a– e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Struc ure 
     
C-17 137. 5 146.33 137.05 135.56 138.62 
C-18 148.81 150. 2 133.07 146.60 136.51 
C-19 122.41 124.8  14 .66 130.58 130.36 
C-20 143. 6 138.72 143.08 128. 3 126.38 
C-21 143. 6 12 .21 126.76 149.8  142.3  
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f– j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Struc ure 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.04  s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz)
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = 4.9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79 
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108.8 (C-8), 143.4 (C-1 ), 151.3 (C-7), 51.4 (C-9), 156.3 (C- a), 166.4 (C-1 ), 180.4 (C-4a), 191.5 (C-3), 197.9 (C-1), 
201.2 (C-1 ). 
NMR 1Н (D SO-d6, ): 1.70 (3H, s, -15), 2.03 (3H s, -10), 2.6  (3H s, -1 ), 6.20 ( H, s, -4). NMR 13С
(DMSO-d6, ): 8.3 (C-10), 27.6 (C-12), 32.0 (C-15), 59.0 (C-9b), 96.9 (C- a),97.3 (C-4  10 .3 (C-6),105.1 (C-2), 05.6
(С-14), 107.3 (C-8), .0 (C-1 ), 151.3 (C-7), 51.4 (C-9), 156.3 (C- a), 166.4 (C-1 ), 180.4 (C-4a), 191.5 (C-3), 197.9
(C-1), 201.2 (C-1 ). 
Table 7. NMR1H spectra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structu e 
     
H-14 s 7.39 s 7.39 s 7.38 s 7.27 s .23 
H-17 s 8.16 s 8.15 s 8.22 s 8.08 s .16 
H-19 
d 8.10 (J = 5.5 
Hz) 
d 8 07 (J = 8.0 
Hz) 
s 9.13 
d 7.34 (J = .5 
Hz) 
d 7.19 (J = 4.9 
Hz) 
H-20 
d 8.84 (J = 5.5 
Hz) 
t 7.66 (J = .9 
Hz) 
d 8 85 (J = .1 
Hz) 
d 7.98 (J = 4.5 
Hz) 
m 6.79 
H-21 
d 8.84 (J = 5.5 
Hz) 
t .21 (J = .1 
Hz) 
m 8.21   
H-22 
d 8.10 (J = 5.5 
Hz) 
d 8 71 (J = 5.1 
Hz) 
d 8.70 (J = 5.1 
Hz) 
 s 2.46 
NH bs 12.37 bs 12.45 --- s 12.78 --- 
OH-3 --- bs 18.82 bs 18.76 bs 18.78 bs 1 .82
OH-7 s 13.28 s 13.05 s 12.96 s 12.49 s 12.27
OH-9 --- bs 10.30 bs 10.30 s 10.23 s 10.27
Table 8. NMR 13C sp ctra of 16a–16e (DMSO-d6, ). 
№ 16a 16b 16c 16d 16e 
Structu e 
     
C-17 137.15 146.33 137.05 135.56 138.62 
C-18 148.81 150.12 133.07 146.60 136.51 
C-19 122.41 124.82 141.66 130.58 130.36 
C-20 143.16 138.72 143.08 128.13 126.38 
C-21 43.16 121.21 26.76 149.84 142.34 
C-22 122.41 140.70 139.95  15.35 
Table 9. NMR1H spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structu e 
     
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12 
H-17 s 7.58 s 7.81 bs .12 s 7.73 s 7.78 
H-19 d 6.77 (J = 3.8 Hz) d 7.08 (J = 3.4 Hz) s 7.0   s 7.43 
H-20 d 6.86 (J = 3.8 Hz) m 6.94  d 6.72 (J = 5.3 Hz) d 7.46 (J = 4.9 Hz)
H-21  d 7.27 (J = 5.0 Hz) s 7.19 d 7.14 (J = .9 Hz) m 7.31 
H-22    s 2.23  
NH bs 9.06 bs 9.48 --- bs 9.11 bs 8.99 
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79
H-14 s 7.11 s 7.08 s 7.04 s 7.09 s 7.12
H-17 s 7.58 s 7.81 bs 8.12 s 7.73 s 7.78
H-19 d 6.77(J = 3.8 Hz)
d 7.08
(J = 3.4 Hz) s 7.04 s 7.43
H-20 d 6.86(J = 3.8 Hz) m 6.94
d 6.72
(J = 5.3 Hz)
d 7.46
(J = 4.9 Hz)
H-21 d 7.27(J = 5.0 Hz) s 7.19
d 7.14
(J = 4.9 Hz) m 7.31
H-22 s 2.23
NH bs 9.06 bs 9.48 — bs 9.11 bs 8.99
OH-3 s 18.79 s 18.78 s 18.79 s 18.78 s 18.79
OH-7 — — — — —
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28
Table 10. NMR 13C spectra of 16f–16j (CDCl3, δ).
№ 16f 16g 16h 16i 16j
Structure
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structu e 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structu e 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structu e 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structu e 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m, ; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m, ; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
   
Molecules 2019, 24, 3711 24 of 34 
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OH-7 --- - --- --- - 
OH-9 s 10.29 s 10.27 s 10.4  s 1 .26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i j 
Structure 
     
C-17 135.97 42.6  138.68 136.47 7.90 
C-18 139.39 8.12 138.72 131.71 6.5  
C-19 128.64 37.70 131.84 138.95 24.77 
C-20 129.92 7.87 110.30 26.73 .09 
C-21 115.29 29. 1 125.35 130.60 26.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 f r ,l,n and MSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.  
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9. 7 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs .93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18. 9 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.3  
Table 12. NMR 13C spectra of 16k–16o (CDCl3 f r ,l,n and MSO-d6 for 16m,o; ). 
№ 16k 16l m 16n o
Structure 
     
C-17 132.37 135.09 6.5  136.37 0 90
C-18 148.62 121.97 6.80 126.39 8 58
C-19 112.28 143.42 09.33 115.74 9 55
C-20 111.72 144.00 12.13 08.03 32 36
C-21 144.26 107.19 22. 4 1 8.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
   
Molecules 2019, 24, 3711 24 of 34 
24 
 
OH-7 --- - --- --- - 
OH-9 s 10.29 s 10.27 s 10.4 s 10.26 s 10.28
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f g 16h 16i j
Structu e 
     
C-17 135.97 42 6 138.68 136.47 7 90
C-18 139.39 8 12 138.72 131.71 6 5
C-19 128.64 37 70 131.84 138.95 24 77
C-20 129.92 7 87 110.30 26.73 09
C-21 115.29 29 1 125.35 130.60 26 59
C-22   13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 f r ,l,n and MSO-d6  m,o; ). 
№ 16k 16l 16m 16n 16o 
Structu e 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30 s 12.60
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 ---
OH-7 bs 12.40 --- s 12.05 --- s 12.71
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.3
Table 12. NMR 13C spectra of 16k–16o (CD l3 f r ,l,n and MSO-d6  m,o; ). 
№ 16k 16l m 16n o
Structu e 
     
C-17 132.37 135.09 136.59 136.37 0 90
C-18 148.62 121.97 126.80 126.39 8 58
C-19 112.28 143.42 109.33 115.74 9 55
C-20 111.72 144.00 112.13 08.03 32 36
C-21 144.26 107.19 122.14 1 8.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 1 o and DMSO-d6 for 16p,q; ). 
№ 16p q 16r 
Structu e 
   
C-17 135.97 142.67 138.68 136.47 137.90
C-18 139.39 138.12 138.72 131.71 136.51
C-19 8 64 3 70 31.84 38 95 4 7
C-20 129.92 127.87 110.30 126.73 126.09
C-21 115.29 129.21 125.35 130.60 126.59
C-22 13.95
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(5-bromothiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (–)-16f : Brown amorphous
powder with a 78% yield
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(thiophen-2-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16g: Brown amorphous
powder with a 71% yield. M.p.: 160–162 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 9. NMR 13C
(100 MHz, CDCl3): see Table 10. HRMS: m/z 509.0707 [M]+ (calcd. for (C24H19O6N332S2)+: 509.0710).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(thiophen-2-yl)methylidene]hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (−)-16g: Brown amorphous
powder with a 70% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(4-bromothiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12- pentaen-3-one (+)-16h: Brown amorphous
powder with a 73% yield. M.p.: 176–178 ◦C dec. NMR H (400 MHz, CDCl3): see Table 9. NMR 13C
(100 MHz, CDCl3): see Table 10. HRMS: m/z 586.9807 [M]+ (calcd. for (C24H18O6N379Br132S1)+: 586.9815).
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(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(4-bromothiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16h: Brown amorphous
powder with a 77% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(3-methylthiophen-2-yl)methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16i: Brown amorphous
powder with a 65% yield. M.p.: 219–220 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 9. NMR 13C
(100 MHz, CDCl3): see Table 10. HRMS: m/z 523.0864 [M]+ (calcd. for (C25H21O6N3S2)+: 523.0866).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(3-methylthiophen-2-yl)
methylidene]hydrazin-1-yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(-)-16i: Brown amorphous powder with a 67% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(thiophen-3-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one amine (+)-16j: Brown amorphous
powder with a 67% yield. M.p.: 152–155 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 9. NMR 13C
(100 MHz, CDCl3): see Table 10. HRMS: m/z 509.0705 [M]+ (calcd. for ((C24H19O6N32S2)+·: 509.0710).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(thiophen-3-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one amine (-)-16j: Brown amorphous
powder with a 70% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(furan-2-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16k: Brown amorphous
powder with a 65% yield. M.p.: 152–154 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 11. NMR 13C
(100 MHz, CDCl3): see Table 12. HRMS: m/z 493.0942 [M]+ (calcd. for (C24H19O7N332S1)+: 493.0938).
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; δ).
№ 16k 16l 16m 16n 16o
Structure
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 13 .71 136.51 
C-19 128.64 137.70 13 .84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 12 .97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 11 .72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.4  s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CD l3, ).
№ 16f 16g 16h 16i 16j 
Struct re 
     
C-17 135.97 142.67 138.6  136.47 137.90 
C-18 139.  138.12 138.72 131.7  136.5  
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.8  110.3  126.73 126.09 
C-21 115.29 129.  125.3  130.6  126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CD l3 for 16k,l,n a d DMSO-d6 for 16m,o; ).
№ 16k 16l 16m 16n 16o 
Struct re 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.3  
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5
Hz) 
s 7.59 s 6.4  m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.8  bs 8.93 --- bs 8.6  --- 
NH ( etAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CD l3 for 16k,l,n a d DMSO-d6 for 16m,o; ).
№ 16k 16l 16m 16n 16o 
Struct re 
     
C-17 132. 7 135.09 136.59 136. 7 130.9  
C-18 148.62 121.97 126.80 126.39 128.5  
C-19 112.28 143. 2 109.33 115.74 119.55 
C-20 111.72 144.00 112. 3 108. 3 132. 6 
C-21 144.26 107.19 122.14 128.0   
C-22    37.09  
Table 13. NMR1H spectra of 16p– r (CD l3 for 16  and DMSO-d6 for 16p,q; ).
№ 16p 16q 16r 
Struct re 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.4  s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CD l3, ). 
№ 16f 16g 16h 16i 16j 
Struct re 
     
C-17 135.97 142.67 138.6  136.47 137.90 
C-18 139.  138.12 138.72 131.7  136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.8  110.3  126.73 126.09 
C-21 115.29 129. 1 125.3  130.6  126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CD l3 for 16k,l,n a d DMSO-d6 for 1 m,o; ). 
№ 16k 16l 16m 16n 16o 
Struct re 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.3  
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2 5 
Hz) 
s 7.59 s 6.4  m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2 2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.8  bs 8.93 --- bs 8.6  --- 
NH ( etAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CD l3 for 16k,l,n a d DMSO-d6 for 1 m,o; ). 
№ 16k 16l 16m 16n 16o 
Struct re 
     
C-17 132. 7 135.09 136.59 136. 7 130.9  
C-18 148.62 121.97 126.80 126.39 128.5  
C-19 112.28 143. 2 109.33 115.74 119.55 
C-20 111.72 144.00 112. 3 108. 3 132. 6 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CD l3 for 16o and DMSO-d6 for 1 p,q; ). 
№ 16p 16q 16r 
Struct re 
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OH-7 --- - - --- --- -- 
OH-9 s 10.29 s 10.27 s 10.4 s 10.26 s 10.28
 
Table 10. NMR 13C spectra of 16f– 6j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.6  136.47 137.90 
C-18 139.  138.12 138.72 131.7  136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.8  110.3  126.73 126.09 
C-21 115.29 129. 1 125.3  130.6  126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n a d DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.3  
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.4  m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.8  bs 8.93 --- bs 8.6  --- 
NH ( etAr)   s 11.30  s 12.60
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n a d DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132. 7 135.09 136.59 136. 7 130.9  
C-18 148.62 121.97 126.80 126.39 128.5  
C-19 112.28 143. 2 109.33 115.74 119.55 
C-20 111.72 144.00 112. 3 108. 3 132. 6 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 fo 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
   
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09
H-19 d 6.65(J = 2. Hz) s 7.59 s 6.46 m 6.39 s 8.00
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17
1 d 7.49(J = 2.2 Hz) m 6.75 s 6.92 6.72
H-22 s 3.91
NH s 8.88 bs 93 — bs .6 —
NH (HetAr) s 11.30 s 12.60
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 —
OH-7 bs 12.40 — s 12.05 — s 12.71
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31
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Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; δ).
№ 16k 16l 16m 16n 16o
Structure
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 1 m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 1 m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 1 p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 1 m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16  (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- -- --- --- -- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 38.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d  for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.3  
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30 s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d  for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 14 .62 121.97 126.80 126.39 128.58 
C-19 1 2.28 43.42 109.33 115.74 19.55 
C-20 111.72 44.00 112.13 108.03 132. 6 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 f r 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --  --  --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.5  
C-19 128.64 137.70 131.84 38.95 124.77 
C-20 1 9.92 127.87 110.30 126.73 126.09 
C-21 115.29 29.2  1 5.35 1 0.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 ---
NH (HetAr)   s 11.30 s 12.60
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 19.55 
C-20 111.72 144.00 112.13 108.03 132. 6 
C-21 144.26 107.19 122.14 128.01  
C-22   37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p q r 
Structure 
   
C-17 132.37 135.09 136.59 136.37 130.90
C-18 148.62 121.97 126.80 126.39 128.58
C- 9 2.28 3 42 09.3 15 74 19 55
C-20 111.72 144.00 112.13 108.03 132.36
C-21 144.26 107.19 122.14 128.01
C-22 37.09
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(furan-2-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16k: Brown amorphous powder
with a 63% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(furan-3-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16l: Brown amorphous powder
with a 78% yield. M.p.: 155–157 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 11. NMR 13C (100 MHz,
CDCl3): see Table 12. HRMS: m/z 493.0941 [M]+ (calcd. for (C24H19O7N332S1)+: 493.0938).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(furan-3-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16l: Brown amorphous powder
with a 75% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1H-pyrrol-2-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16m: Brown amorphous
powder with a 21% yield. M.p.: 155–157 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see Table 11. NMR 13C
(100 MHz, DMSO-d6): see Table 12. HRMS: m/z 492.1090 [M]+ (calcd. for (C24H20O6N432S1)+: 492.1080).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1H-pyrrol-2-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16m: Brown amorphous
powder with a 20% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1-methyl-pyrrol-2-yl) methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16n: Brown amorphous
powder with an 80% yield. M.p.: 196–198 ◦C dec. NMR 1H (400 MHz, CDCl3): see Table 11. NMR 13C
(100 MHz, CDCl3): see Table 12. HRMS: m/z 506.1258 [M]+ (calcd. for (C25H22O6N4S1)+: 506.1255).
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1-methyl-pyrrol-2-yl) methylidene]hydrazin-1-
yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (−)-16n: Brown amorphous
powder with an 81% yield.
5-[(1E)-(2-{4-[(1R)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7]trideca-2(7),3,5,
9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]-1H-imidazol-1-ium bromide (+)-16o: Brown
amorphous powder with a 79% yield. M.p.: 168–172 ◦C dec. NMR 1H (400 MHz, DMSO-d6):
see Table 11. NMR 13C (100 MHz, DMSO-d6): see Table 12. HRMS: m/z 493.1045 [M]+ (calcd.
for (C23H19O6N5S1)+: 493.1051). Anal. Calcd. for C25H21BrO6N4S1 (585.42): Br, 13.91%. Found:
Br, 13.90%.
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5-[(1E)-(2-{4-[(1S)-12-Acetyl-3,5,11-trihydroxy-1,4-dimethyl-13-oxo-8-oxatricyclo[7.4.0.02,7]trideca-2(7),3,5,
9,11-pentaen-6-yl]-1,3-thiazol-2-yl}hydrazin-1-ylidene)methyl]-1H-imidazol-1-ium bromide (−)-16o: Brown
amorphous powder with a 79% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1H-indole-3-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16p: Brown amorphous
powder with an 80% yield. M.p.: 191–192 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see Table 13. NMR 13C
(100 MHz, DMSO-d6): see Table 14. HRMS: m/z 542.1243 [M]+ (calcd. for (C28H22O6N432S1)+: 542.1255).
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; δ).
№ 16p 16q 16r
Structure
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
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OH-7 --- --- --- --- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 127.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16  (CDCl3 f r 16k,l,n and DMSO- 6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8.00 
H-20 m 6.45 s 7.39 s 6.14 m 6.11 s 9.17 
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 6.92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)  s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 s 18.79 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16  (CDCl3 f r 16k,l,n and DMSO- 6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO- 6 for 16p,q; ).
№ 16p 16q 16r 
Structure 
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OH-7 - - --- -- -- --- 
OH-9 s 10.29 s 10.27 s 10.40 s 10.26 s 10.28 
 
Table 10. NMR 13C spectra of 16f–16j (CDCl3, ). 
№ 16f 16g 16h 16i 16j 
Structure 
     
C-17 135.97 142.67 138.68 136.47 137.90 
C-18 139.39 138.12 138.72 131.71 136.51 
C-19 128.64 137.70 131.84 138.95 124.77 
C-20 129.92 1 7.87 110.30 126.73 126.09 
C-21 115.29 129.21 125.35 130.60 126.59 
C-22    13.95  
Table 11. NMR1H spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l m 16n 16o 
Structure 
     
H-14 s 7.15 s 7.11 s 7.24 s 7.09 s 7.37 
H-17 s 7.60 s 7.63 s 7.94 s 7.68 s 8.09 
H-19 
d 6.65 (J = 2.5 
Hz) 
s 7.59 s 6.46 m 6.39 s 8 00
H-20 m 6.45 s 7 39 s 6.14 m 6.11 s 9 7
H-21 
d 7.49 (J = 2.2 
Hz) 
m 6.75 s 92 s 6.72  
H-22    s 3.91  
NH s 8.88 bs 8.93 --- bs 8.68 --- 
NH (HetAr)   s 11.30  s 12.60 
OH-3 s 18.77 s 18.79 bs 18.77 9 --- 
OH-7 bs 12.40 --- s 12.05 --- s 12.71 
OH-9 s 10.26 s 10.95 s 10.28 s 10.28 s 10.31 
Table 12. NMR 13C spectra of 16k–16o (CDCl3 for 16k,l,n and DMSO-d6 for 16m,o; ). 
№ 16k 16l 16m 16n 16o 
Structure 
     
C-17 132.37 135.09 136.59 136.37 130.90 
C-18 148.62 121.97 126.80 126.39 128.58 
C-19 112.28 143.42 109.33 115.74 119.55 
C-20 111.72 144.00 112.13 108.03 132.36 
C-21 144.26 107.19 122.14 128.01  
C-22    37.09  
Table 13. NMR1H spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16p 16q 16r 
Structure 
   
H-14 s 7.24 s 7.22 s 7.12
H-17 s 8.30 s 8.33 s 7.68
H-19 m 8.21 d 6.69 (J = 3.3 Hz,AB-system)
H-20 d 6.66 (J = 3.3 Hz,AB-system)
H-21 s 7.45 m 7.34
H-22 m 7.21 m 7.13
H-23 m 7.21 m 7.13 s 7.62
H-24 d 7.83(J = 2.7 Hz) m 8.10
H-25 d 7.52 (J = 7.5 Hz)
H-26 s 2.51 m 7.21–7.30
H-27 m 7.21–7.30
NH s 12.08 s 12.00 —
NH (HetAr) s 11.59 s 11.51
OH-3 bs 18.82 bs 18.82 s 18.76
OH-7 s 13.03 bs 13.05 —
OH-9 s 10.30 s 10.31 s 10.26
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1H-indole-3-yl)methylidene] hydrazin-1-yl]-1,3-
thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16p: Brown amorphous powder
with a 79% yield.
(2R)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1H-2-methyl-indole-3-yl) methylidene]hydrazin-
1-yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16q: Brown amorphous
powder with an 89% yield. M.p.: 186–189 ◦C dec. NMR 1H (400 MHz, DMSO-d6): see Table 13. NMR 13C
(100 MHz, DMSO-d6): see Table 14. HRMS: m/z 556.1415 [M]+ (calcd. for (C29H24O6N4S1)+: 556.1411).
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Table 14. NMR 13C spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; δ).
№ 16n 16o 16r
Structure
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H-14 s 7.24 s 7.22 s 7.12 
H-17 s 8.30 s 8.33 s 7.68 
H-19 m 8.21  
d 6.69 (J = 3.3 Hz, 
AB-system) 
H-20   
d 6.66 (J = 3.3 Hz, 
AB-system) 
H-21 s 7.45 m 7.34  
H-22 m 7.21 m 7.13  
H-23 m 7.21 m 7.13 s 7.62 
H-24 d 7.83 (J = 2.7 Hz) m 8.10  
H-25   d 7.52 (J = 7.5 Hz) 
H-26  s 2.51 m 7.21–7.30 
H-27   m 7.21–7.30 
NH s 12.08 s 12.00 --- 
NH (HetAr) s 11.59 s 11.51  
OH-3 bs 18.82 bs 18.82 s 18.76 
OH-7 s 13.03 bs 13.05 --- 
OH-9 s 10.30 s 10.31 s 10.26 
Table 14. NMR 13C spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16n 16o 16r 
Structure 
   
C-17 140.39 140.29 132.95 
C-18 111.35 107.42 148.80 
C-19 130.13 135.76 108.17 
C-20 137.11 139.52 114.29 
C-21 111.95 110.99 153.82 
C-22 121.59 120.63 131.35 
C-23 120.59 120.46 123.92 
C-24 122.64 121.83 134.78 
C-25 124.02 124.02 127.90 
C-26  11.53 129.91 
C-27   122.03 
Table 15. NMR1H spectra of 17a–17f (CDCl3, ). 
 
№ 17a 17b 17c 17d 17e 17f 
H-14 s 7.09 s 7.02 m 7.05 s 7.06 s 7.09 s 7.07 
H-17 
m 7.45–
7.65 
s 7.81 s 7.68 s 7.64 s 7.60 s 7.85 
H-19 
m 7.45–
7.65 
s 7.71 s 7.62 s 7.61 s 7.56 s 7.71 
H-22 
m 6.82–
6.97 
d 6.77 (J = 8.6 
Hz) 
d 6.78 (J = 7.0 
Hz) 
m 6.82 
d 6.51 (J = 7.9 
Hz) 
m 6.90 
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H-14 s 7.24 s 7.22 s 7.12 
H-17 s 8.30 s 8.33 s 7.68 
H-19 m 8.21  
d 6.69 (J = 3.3 Hz, 
AB-system) 
H-20   
d 6.66 (J = 3.3 Hz, 
AB-system) 
H-21 s 7.45 m 7.34  
H-22 m 7.21 m 7.13  
H-23 m 7.21 m 7.13 s 7.62 
H-24 d 7.83 (J = 2.7 Hz) m 8.10  
H-25   d 7.52 (J = .  Hz) 
H-26  s 2.51 m 7.21–7.30 
H-27   m 7.21–7.30 
NH s 12.08 s 12.00 --- 
NH (HetAr) s 11.59 s 11.51  
OH-3 bs 18.82 bs 18.82 s 18.76 
OH-7 s 13.03 bs 13.05 --- 
OH-9 s 10.30 s 10.31 s 10.26 
Table 14. NMR 13C spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16n 16o 16r 
Structure 
   
C-17 140.39 140.29 132.95 
C-18 111.35 107.42 148.80 
C-19 130.13 135.76 108.17 
C-20 137.11 139.52 114.29 
C-21 111.95 110.99 153.82 
C-22 121.59 120.63 131.35 
C-23 120.59 120.46 123.92 
C-24 122.64 121.83 134.78 
C-25 124.02 124.02 127.90 
C-26  11.53 129.91 
C-27   122.03 
Table 15. NMR1H spectra of 17a–17f (CDCl3, ). 
 
№ 17a 17b 17c 17d 17e 17f 
H-14 s 7.09 s 7.02 m 7.05 s 7.06 s 7.09 s 7.07 
H-17 
m 7.45–
7.65 
s 7.81 s 7.68 s 7.64 s 7.60 s 7.85 
H-19 
m 7.45–
7.65 
s 7.71 s 7.62 s 7.61 s 7.56 s 7.71 
H-22 
m 6.82–
6.97 
d 6.77 (J = 8.6 
Hz) 
d 6.78 (J = 7.0 
Hz) 
m 6.82 
d 6.51 (J = 7.9 
Hz) 
m 6.90 
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H-14 s 7.24 s 7.22 s 7.12 
H-17 s 8.30 s 8.33 s 7.68 
H-19 m 8.21  
d 6.69 (J = 3.3 Hz, 
AB-system) 
H-20   
d 6.66 (J = 3.3 Hz, 
AB-system) 
H-21 s 7.45 m 7.34  
H-22 m 7.21 m 7.13  
H-23 m 7.21 m 7.13 s 7.62 
H-24 d 7.83 (J = 2.  Hz) m 8.10  
H-25   d 7.52 (J = 7.5 Hz) 
H-26  s 2.51 m 7.21–7.30 
H-27   m 7.21–7.30 
NH s 12.08 s 12.00 --- 
NH (HetAr) s 11.59 s 11.51  
OH-3 bs 18.82 bs 18.82 s 18.76 
OH-7 s 13.03 bs 13.05 --- 
OH-9 s 10.30 s 10.31 s 10.26 
Table 14. NMR 13C spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16n 16o 16r 
Structure 
   
C-17 140.39 140.29 132.95 
C-18 111.35 107.42 148.80 
C-19 130.13 135.76 108.17 
C-20 137.11 39.52 114.29 
C-21 11.95 110.99 153.82 
C-22 121.59 120.63 131.35 
C-23 120.59 120.46 123.92 
C-24 122.64 121.83 134.78 
C-25 124.02 124.02 127.90 
C-26  11.53 129.91 
C-27   122.03 
Table 15. NMR1H spectra of 17a–17f (CDCl3, ). 
 
№ 17a 17b 17c 17d 17e 17f 
H-14 s 7.09 s 7.02 m 7.05 s 7.06 s 7.09 s 7.07 
H-17 
m 7.45–
7.65 
s 7.81 s 7.68 s 7.64 s 7.60 s 7.85 
H-19 
m 7.45–
7.65 
s 7.71 s 7.62 s 7.61 s 7.56 s 7.71 
H-22 
m 6.82–
6.97 
d 6.77 (J = 8.  
Hz) 
d . 8 (J = 7.0 
Hz) 
m 6.82 
d 6.51 (J = 7.9 
Hz) 
m 6.90 
C-17 140.39 140.29 132.95
C-18 111.35 107.42 148.80
C-19 0 3 5 76 08 17
C-20 137.11 139.52 114.29
C-21 111.95 110.99 153.82
C-22 1.59 0.6 1.35
C-23 120.59 120.46 123.92
C-24 122.64 121.83 134.78
C-25 124.02 124.02 127.90
C-26 1 .53 129.91
C-27 122.03
(2S)-4-Acetyl-5,11,13-trihydroxy-2,12-dimethyl-10-{2-[(E)-2-[(1H-3-methyl-indole-3-yl) methylidene]hydrazin-
1-yl]-1,3-thiazol-4-yl}-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16q: Brown amorphous
powder with an 88% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-{[5-(3-chlorophenyl)furan-2-yl]methylidene}hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,
13-trihydroxy-2,12-dimethyl-8-oxatricyclo[ .4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (+)-16r: Brown
amorphous powder with an 89% yield. M.p.: 148–151 ◦C dec. NMR 1H (400 MHz, DMSO-d6):
see Table 13. NMR 13C (100 MHz, DMSO-d6): see Table 14. HRMS: m/z 603.0860 [M]+ (calcd. for
(C30H22ClO7N3S1)+: 603.0867).
(2S)-4-Acetyl-10-{2-[(E)-2-{[5-(3-chlorophenyl)furan-2-yl]methylidene}hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,
13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one (-)-16r): Brown
amorphous powder in 87% yield. (2R)-4-Acetyl-10-{2-[(E)-2-({3-[(4-fluorophenoxy)methyl]-4-methoxyphenyl}
methylidene)hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-
1(9),4,6,10,12-pentaen-3-one (+)-17a: Orange amorphous powder with a 79% yield. M.p.: 120–122 ◦C
dec. NMR 1H (400 MHz, CDCl3): see Table 15. NMR 13C (100 MHz, CDCl3): see Table 16. HRMS: m/z
657.1557 [M]+ (calcd. for (C34H28O8N3F132S1)+: 657.1576).
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(4-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-yl]-1,3-
thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(-)-17a: Orange amorphous powder with a 77% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(3-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-yl]-1,3-
thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(+)-17b: Orange amorphous powder with a 70% yield. M.p.: 119–122 ◦C dec. NMR 1H (400 MHz,
CDCl3): see Table 15. NMR 13C (100 MHz, CDCl3): see Table 16. HRMS: m/z 657.1590 [M]+ (calcd. for
(C34H28O8N3F132S1)+: 657.1576).
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Table 15. NMR1H spectra of 17a–17f (CDCl3, δ).
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H-14 s 7.24 s 7.22 s 7.12 
H-17 s 8.30 s 8.33 s 7.68 
H-19 m 8.21  
d 6.69 (J = 3.3 Hz, 
AB-system) 
H-20   
d 6.66 (J = 3.3 Hz, 
AB-system) 
H-21 s 7.45 m 7.34  
H-22 m 7.21 m 7.13  
H-23 m 7.21 m 7.13 s 7.62 
H-24 d 7.83 (J = 2.7 Hz) m 8.10  
H-25   d 7.52 (J = 7.5 Hz) 
H-26  s 2.51 m 7.21–7.30 
H-27   m 7.21–7.30 
NH s 12.08 s 12.00 --- 
NH (HetAr) s 11.59 s 11.51  
OH-3 bs 18.82 bs 18.82 s 18.76 
OH-7 s 13.03 bs 13.05 --- 
OH-9 s 10.30 s 10.31 s 10.26 
Table 14. NMR 13C spectra of 16p–16r (CDCl3 for 16o and DMSO-d6 for 16p,q; ). 
№ 16n 16o 16r 
Structure 
   
C-17 140.39 140.29 132.95 
C-18 111.35 107.42 148.80 
C-19 130.13 135.76 108.17 
C-20 137.11 139.52 114.29 
C-21 111.95 110.99 153.82 
C-22 121.59 120.63 131.35 
C-23 120.59 120.46 123.92 
C-24 122.64 121.83 134.78 
C-25 124.02 124.02 127.90 
C-26  11.53 129.91 
C-27   122.03 
Table 15. NMR1H spectra of 17a–17f (CDCl3, ). 
 
№ 17a 17b 17c 17d 17e 17f 
H-14 s 7.09 s 7.02 m 7.05 s 7.06 s 7.09 s 7.07 
H-17 
m 7.45–
7.65 
s 7.81 s 7.68 s 7.64 s 7.60 s 7.85 
H-19 
m 7.45–
7.65 
s 7.71 s 7.62 s 7.61 s 7.56 s 7.71 
H-22 
m 6.82–
6.97 
d 6.77 (J = 8.6 
Hz) 
d 6.78 (J = 7.0 
Hz) 
m 6.82 
d 6.51 (J = 7.9 
Hz) 
m 6.90 
№ 17a 17b 17c 17d 17e 17f
H-14 s 7.09 s 7.02 m 7.05 s 7.06 s 7.09 s 7.07
H-17 m 7.45–7.65 s 7.81 s 7.68 s 7.64 s 7.60 s 7.85
H-19 m 7.45–7.65 s 7.71 s 7.62 s 7.61 s 7.56 s 7.71
H-22 m 6.82–6.97 d 6.77(J = 8.6 Hz)
d 6.78
(J = 7.0 Hz) m 6.82
d 6.51
(J = 7.9 Hz) m 6.90
H-23 m 7.45–7.65 d 7.44(J = 8.6 Hz)
d 7.44
(J = 7.0 Hz)
d 7.48
(J = 7.3 Hz)
d 7.48
(J = 8.3 Hz)
d 7.41
(J = 8.1 Hz)
H-24 s 5.00 s 5.07 s 5.09 s 4.97 s 5.00 s 5.04
H-25 s 3.83 s 3.79 s 3.79 s 3.82 s 3.84 s 3.83
H-27 m 6.82–6.97 m 6.90–7.10 s 6.91 m 7.01 d 8.47(J = 8.5 Hz)
H-28 m 6.82–6.97 m 6.90–7.10 m 7.05 d 6.82(J = 7.9 Hz) m 6.90
H-29 m 6.90–7.10 m 7.05
H-30 m 6.82–6.97 m 7.05 m 7.01 t 6.41(J = 8.4 Hz) m 7.12
H-31 m 6.82–6.97 m 6.90–7.10 m 6.82
NH bs 8.92 — bs 9.45 bs 9.45 bs 8.93 bs 9.60
OH-3 s 18.78 s 18.77 s 18.76 s 18.77 s 18.78 s 18.75
OH-7 — — — — bs 12.21 —
OH-9 s 10.24 s 10.29 s 10.23 s 10.24 s 10.23 s 10.22
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(3-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-yl]-1,3-
thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(-)-17b: Orange amorphous powder with a 65% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(2-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-yl]-1,3-
thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(+)-17c: Orange amorphous powder with a 94% yield. M.p.: 118–121 ◦C dec. NMR 1H (400 MHz,
CDCl3): see Table 15. NMR 13C (100 MHz, CDCl3): see Table 16. HRMS: m/z 657.1590 [M]+ (calcd. for
(C34H28O8N3F132S1)+: 657.1576).
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(2-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-yl]-1,3-
thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(-)-17c: Orange amorphous powder with a 97% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(3-chloro-4-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-
3-one (+)-17d: Orange amorphous powder with a 95% yield. M.p.: 123–126 ◦C dec. NMR 1H (400 MHz,
CDCl3): see Table 15. NMR 13C (100 MHz, CDCl3): see Table 16. HRMS: m/z 691.1194 [M]+ (calcd. for
(C34H27O8N335Cl1F132S1)+: 691.1186).
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Table 16. NMR 13C spectra of 17a–17f (CDCl3, δ).
№ 17a 17b 17c 17d 17e 17f
C-17 142.43 143.82 143.09 142.48 142.30 142.35
C-18 125.64 125.43 125.30 125.01 124.84 125.12
C-19 127.14 127.14 127.13 127.07 127.11 127.14
C-20 126.07 125.93 126.00 126.04 126.20 126.28
C-21 158.06 158.19 158.08 158.03 158.10 158.05
C-22 110.26 110.21 110.14 110.25 110.41 110.34
C-23 127.69 128.96 127.93 127.96 128.06 128.65
C-24 65.26 65.91 65.88 65.32 65.16 65.22
C-25 55.47 55.46 55.36 55.46 55.53 55.78
C-26 d 154.74(J = 2.2 Hz)
d 146.61
(J = 10 Hz)
d 146.61
(J = 11 Hz)
d 154.81
(J = 2.4 Hz)
t 160.57
(J = 13.4 Hz)
d 150.14
(J = 2.4 Hz)
C-27 d 115.56(J = 12 Hz) 115.50
d 151.42
(J = 247 Hz) 116.44
d 162.68
(J = 244 Hz)
d 121.50
(J = 10 Hz)
C-28 d 115.83(J = 3.2 Hz)
d 151.84
(J = 249 Hz)
d 116
(J = 16 Hz)
120.83
(J = 19 Hz)
t 96.47
(J = 29 Hz)
d 118.51
(J = 28 Hz)
C-29 d 155.68(J = 239 Hz)
d 116.00
(J = 19 Hz)
d 121.24
(J = 7 Hz)
d 151.54
(J = 247 Hz)
d 162.55
(J = 244 Hz)
d 156.08
(J = 247 Hz)
C-30 d 115.83(J = 3.2 Hz)
d 124.08
(J = 3.5 Hz)
d 124.10
(J = 3.4 Hz)
d 116.51
(J = 22 Hz) m 98.50
d 114.06
(J = 21 Hz)
C-31 d 115.56(J = 12 Hz)
d 121.25
(J = 8 Hz) 115.41
d 114.30
(J = 6.7 Hz) m 98.50
d 114.67
(J = 9.4 Hz)
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(3-chloro-4-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3
-one (-)-17d: Orange amorphous powder with a 97% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(3,4-difluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3
-one (+)-17e: Orange amorphous powder with a 96% yield. M.p.: 127–130 ◦C dec. NMR 1H (400 MHz,
CDCl3): see Table 15. NMR 13C (100 MHz, CDCl3): see Table 16. HRMS: m/z 675.1474 [M]+ (calcd. for
(C34H27O8N3F232S1)+: 675.1481).
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(3,4-difluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-yl]-1,3-
thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen-3-one
(-)-17e: Orange amorphous powder with a 93% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(4-chloro-3-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen
-3-one (+)-17f : Orange amorphous powder with a 95% yield. M.p.: 129–133 ◦C dec. NMR 1H (400 MHz,
CDCl3): see Table 15. NMR 13C (100 MHz, CDCl3): see Table 16. HRMS: m/z 691.1195 [M]+ (calcd. for
(C34H27O8N335Cl1F132S1)+: 691.1186).
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(4-chloro-3-fluorophenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen
-3-one (-)-17f : Orange amorphous powder with a 94% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-[(3-{[(2-tert-butyl-5-methylphenyl)sulfanyl]methyl}-4-methoxyphenyl)methylidene]
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
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12-pentaen-3-one (+)-17g: Orange amorphous powder with a 92% yield. M.p.: 103–105 ◦C dec. NMR
1H (400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, CDCl3): see Table 18. HRMS: m/z 725.2230
[M]+ (calcd. for (C39H39O7N332S2)+: 725.2224).
Table 17. NMR1H spectra of 17g–17k (CDCl3 for g–j and DMSO-d6 for k, δ).
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№ 17g 17h 17i 17j 17k 
H-14 s 7.08 s 7.07 s 7.00 s 6.98 s 7.23 
H-17 s 7.49 s 7.69 bs 7.98 s 8.13 s 7.26 
H-19 s 7.32 s 7.64 bs 7.98 s 8.05 s 7.67 
H-22 
d 6.76 
(J = 8.5 Hz) 
m 6.76 d 6.56 (J = 8.0 Hz) d 6.46 (J = 8.1 Hz) 
d 7.08 
(J = 8.4 Hz) 
H-23 m 7.40 d 7.51 (J = 8.3 Hz) m 7.34 m 6.84-7.03 
d 7.50 
(J = 8.4 Hz) 
H-24 s 4.04 s 4.99 s 4.11 s 4.19 s 5.27 
H-25 s 3.77 s 3.84 s 3.61 bs 3.51 s 3.85 
H-26   s 3.29 bs 3.51  
H-27 s 1.22 (t-Bu) 
d 6.88 
(J = 2.4 Hz) 
s 3.48 m 3.85  
H-28 m 7.23 s 2.34 (Me)    
H-29 m 7.08  m 6.83–6.94 m 6.84–7.03 s 2.40 
H-30 s 2.33 (Me) 
d 7.21 
(J = 8.6 Hz) 
m 6.83–6.94 m 3.85 (OMe) s 2.59 
H-31 m 7.32 
d 6.83 
(J = 8.5 Hz) 
 m 6.84–7.03  
H-32   m 6.83–6.94 m 6.84–7.03  
H-33   m 6.83–6.94 m 6.84–7.03  
NH bs 9.09 bs 9.56 bs 11.22 bs 11.22 bs 12.28 
OH-3 s 18.79 s 18.79 bs 18.7 bs 18.76 bs 18.80 
OH-7 --- --- bs 12.64 bs 12.63 bs 12.77 
OH-9 s 10.26 s 10.27 s 10.24 s 10.23 s 10.30 
№ 17g 17h 17i 17j 17k
H-14 s 7.08 s 7.07 s 7.00 s 6.98 s 7.23
H-17 s 7.49 s 7.69 bs 7.98 s 8.13 s 7.26
H-19 s .32 s 7.64 bs 7.98 s 8.05 s 7.67
H-22 d 6.76(J = 8.5 Hz) m 6.76
d 6.56
(J = 8.0 Hz)
d 6.46
(J = 8.1 Hz)
d 7.08
(J = 8.4 Hz)
H-23 m 7.40 d 7.51(J = 8.3 Hz) m 7.34 m 6.84-7.03
d 7.50
(J = 8.4 Hz)
H-24 s 4.04 s 4.99 s 4.11 s 4.19 s 5.27
H-25 s 3.77 s 3.84 s 3.61 bs 3.51 s 3.85
H-26 s 3.29 bs 3.51
H-27 s 1.22 (t-Bu) d 6.88(J = 2.4 Hz) s 3.48 m 3.85
H-28 m 7.23 s 2.34 (Me)
H-29 m 7.08 m 6.83–6.94 m 6.84–7.03 s 2.40
H-30 s 2.33 (Me) d 7.21(J = 8.6 Hz) m 6.83–6.94 m 3.85 (OMe) s 2.59
H-31 m 7.32 d 6.83(J = 8.5 Hz) m 6.84–7.03
H-32 m 6.83–6.94 m 6.84–7.03
H-33 m 6.83–6.94 m 6.84–7.03
NH bs 9.09 bs 9.56 bs 11.22 bs 11.22 bs 12.28
OH-3 s 18.79 s 18.79 bs 18.7 bs 18.76 bs 18.80
OH-7 — — bs 12.64 bs 12.63 bs 12.77
OH-9 s 10.26 s 10.27 s 10.24 s 10.23 s 10.30
(2S)-4-Acetyl-10-{2-[(E)-2-[(3-{[(2-tert-butyl-5-methylphenyl)sulfanyl]methyl}-4-methoxyphenyl)methylidene]
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (-)-17g: Orange amorphous powder with a 90% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(4-chloro-3-methylphenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen
-3-one (+)-17h: Orange amorphous powder with a 56% yield. M.p.: 125–127 ◦C dec. NMR 1H (400 MHz,
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CDCl3): see Table 17. NMR 13C (100 MHz, CDCl3): see Table 18. HRMS: m/z 687.1432 [M]+ (calcd. for
(C35H30O8N332S135Cl1)+: 687.1437).
Table 18. NMR 13C spectra of 17g–17k (CDCl3 for g–j and DMSO-d6 for k, δ).
№ 17g 17h 17i 17j 17k
C-17 142.74 143.61 141.77 141.03 142.40
C-18 125.70 125.47 127.27 127.72 123.52
C-19 127.77 127.19 129.01 129.77 126.09
C-20 126.47 125.90 127.27 127.72 126.99
C-21 158.61 158.08 158.70 158.36 157.16
C-22 110.38 110.21 110.52 110.89 110.26
C-23 128.79 129.46 131.17 131.96 128.05
C-24 32.56 64.74 48.25 47.48 47.97
C-25 55.50 55.45 55.35 55.26 55.41
C-26 134.44 157.12 54.52 54.64 140.77
C-27 149.06 (CAr)31.09 (t-Bu) 113.28 51.98 52.05 145.97
C-28 129.57 127.9220.25 (Me) 146.65 151.77 130.90
C-29 128.79 136.97 d 115.45(J = 22 Hz)
139.11 (CAr)
54.96 (O-Me) 11.32
C-30 135.72 (CAr)19.73 (Me) 126.01
d 118.53
(J = 7.43 Hz) 110.89 14.07
C-31 123.63 117.22 d 156.02(J = 240 Hz) 118.75
C-32 d 118.53(J = 7.43 Hz) 124.02
C-33 d 115.45(J = 22 Hz) 121.04
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(4-chloro-3-methylphenoxy)methyl]-4-methoxyphenyl}methylidene)hydrazin-1-
yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,12-pentaen
-3-one (-)-17h: Orange amorphous powder with a 51% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-[(3-{[4-(4-fluorophenyl)piperazin-1-yl]methyl}-4-methoxyphenyl)methylidene]
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (+)-17i: Orange amorphous powder with a 91% yield. M.p.: 175–179 ◦C dec. NMR 1H
(400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, CDCl3): see Table 18. HRMS: m/z 725.2274 [M]+
(calcd. for (C38H36O7N5F1S1)+: 725.2314).
(2S)-4-Acetyl-10-{2-[(E)-2-[(3-{[4-(4-fluorophenyl)piperazin-1-yl]methyl}-4-methoxyphenyl)methylidene]
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (-)-17i: Orange amorphous powder with an 85% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-[(3-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-4-methoxyphenyl)methylidene]
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (+)-17j: Orange amorphous powder with a 50% yield. M.p.: 171–175 ◦C dec. NMR 1H
(400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, CDCl3): see Table 18. HRMS: m/z 737.8204 [M]+
(calcd. for (C39H39O8N5S1)+: 737.8207).
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(2S)-4-Acetyl-10-{2-[(E)-2-[(3-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-4-methoxyphenyl)methylidene]
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (-)-17j: Orange amorphous powder with a 53% yield.
(2R)-4-Acetyl-10-{2-[(E)-2-({3-[(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)methyl]-4-methoxyphenyl}methylidene)
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (+)-17k: Orange amorphous powder with an 85% yield. M.p.: 160–165 ◦C dec. NMR
1H (400 MHz, CDCl3): see Table 17. NMR 13C (100 MHz, CDCl3): see Table 18. HRMS: m/z 686.1806
[M]+ (calcd. for (C33H30O9N632S1)+: 686.1790).
(2S)-4-Acetyl-10-{2-[(E)-2-({3-[(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)methyl]-4-methoxyphenyl}methylidene)
hydrazin-1-yl]-1,3-thiazol-4-yl}-5,11,13-trihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(9),4,6,10,
12-pentaen-3-one (-)-17k: Orange amorphous powder with an 87% yield.
3.2. Real-Time Detection of Tdp1 Activity
A fluorophore quencher-coupled DNA-biosensor for real-time measurement of Tdp1 cleavage
activity was recently designed in our laboratory [9]. The biosensor is a 16-mer single-stranded
oligonucleotide containing both a 5’-FAM fluorophore donor and a quenching 3’-BHQ1 moiety.
Recombinant protein Tdp1 was expressed in EsCherichia coli (pET 16B plasmid containing Tdp1
cDNA provided by Dr. K.W. Caldecott, University of Sussex, United Kingdom) and isolated as
described [3,50]. The reaction mixture in a final volume 200 µL contained Tdp1 reaction buffer (50 mM
Tris-HCl, 50 mM NaCl, 7 mM β-mercaptoethanol), 50 nM oligonucleotide substrate, and varied
concentrations of potential inhibitor. Purified Tdp1 was added in a final concentration of 1.5 nM.
The reaction mixtures were incubated at a constant temperature of 26 ◦C in a POLARstar OPTIMA
fluorimeter, BMG LABTECH, GmbH, to measure fluorescence intensity every minute (Ex485/Em520 nm).
Tdp1 inhibition was calculated by comparing the rate of increase in fluorescence of the biosensor in the
presence of the compound to that of DMSO (1.5%) control wells. The measurements were carried out
in at least two independent experiments. IC50 values were determined using a six-point concentration
response curve. The data were imported into the MARS Data Analysis 2.0 program (BMG LABTECH)
and the slope during the linear phase (data from 0 to 7 min) was calculated.
3.3. Binding Assay
pET-28a(+) plasmid encoding recombinant Tdp1 (residues 149–608) was obtained from GenScript.
E. coli BL21(DE3) was used for recombinant protein production. Protein production was induced
with 1 mM IPTG at 28 ◦C with overnight incubation. Tdp1 was purified using affinity and size
exclusion chromatography. Fluorescence was measured using a PerkinElmer EnSpire Multimode
Reader. Tdp1 concentration was 10 µM with varying compound concentrations. The buffer was 20 mM
Tris and 250 mM NaCl (pH 8). The excitation wavelength was 280 nm and intrinsic fluorescence was
measured at 350 nm. Control experiments with Tdp1 or the compound on its own were also conducted.
Background fluorescence arising from the compounds was subtracted from the final spectrum. The
total volume per well was 30 µL. The dissociation constant (KD) was calculated using Equation (1),
which takes non-specific binding into account.
y = Bmaxx/(KD + x) + Nsx (1)
where y denotes the changes in fluorescence intensity; x denotes the concentration of the compounds;
Bmax denotes the maximum changes in fluorescence intensity; and Ns is a scaling factor for non-specific
binding. Experiments were conducted in triplicate.
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3.4. Cytotoxicity Assay
Analysis of the intrinsic toxicity of the compounds was examined against human cell line HeLa
(cervical cancer) using a standard MTT test [51] by colorimetric measurement of the amount of
formazan converted from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide in cells
exposed to the compounds. The cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM),
with 40 µg/mL gentamicin, 50 IU/mL penicillin, 50 µg/mL streptomycin (MP Biomedicals), and in the
presence of 10% fetal bovine serum (Biolot) in a 5% CO2 atmosphere. After formation of a 30–50%
monolayer, tested compounds were added to the medium (the volume of added reagents was 1/100
of the total volume of the culture medium, the amount of DMSO was 1% of the final volume), and
the cell culture was monitored for three days. Control cells were grown in the presence of 1% DMSO.
The measurements were carried out in three parallel experiments.
3.5. Modeling and Screening
The compounds were docked against the crystal structure of Tdp1 (PDB ID: 6DIE, resolution
1.78 Å) [34], which was obtained from the Protein Data Bank (PDB) [52,53]. The Scigress version FJ
2.6 program [54] was used to prepare the crystal structure for docking (i.e., the hydrogen atoms were
added, the co-crystallized ligand benzene-1,2,4-tricarboxylic acid was removed, and the crystallographic
water molecules in one instance and the other with water molecules, HOH 814, 821 and 1078.
The Scigress software suite was also used to build the inhibitors and the MM2 [55] force field was
used to optimize the structures. The docking center was defined as the position of a carbon on the
ring of benzene-1, 2, 4-tricarboxylic acid (x = −6.052, y = −14.428, z = 33.998) with a 10 Å radius. Fifty
docking runs were allowed for each ligand with the default search efficiency (100%). The basic amino
acids lysine and arginine were defined as protonated. Furthermore, aspartic and glutamic acids were
assumed to be deprotonated. The GoldScore (GS) [56] and ChemScore (CS) [57,58], improved the
piecewise linear potential (ChemPLP) [59] and Astex statistical potential (ASP) [60] scoring functions
were implemented to validate the predicted binding modes and relative energies of the ligands using
the GOLD v5.4.1 software suite.
The QikProp 3.2 [61] software package was used to calculate the molecular descriptors of the
molecules. The reliability of it is established for the calculated descriptors [62]. The known drug index
(KDI) was calculated from the molecular descriptors [37].
4. Conclusions
Two sets of new hydrazinothiazole derivatives of usnic acid were synthesized. Most of these
compounds were found to be very potent inhibitors of Tdp1 with IC50 in a low nanomolar range.
The ability of several compounds to enhance the cytotoxicity of topotecan, an established topoisomerase
1 poison, was demonstrated. Thus, a new structural type of Tdp1 inhibitors was found. These are
promising candidates for adjunctive therapy to enhance the efficacy of Top1 poisons.
Supplementary Materials: The following are available online. Tables S1–S16 (NMR data), Copies of NMR spectra
of the products, Figures with changes in intrinsic fluorescence intensity of Tdp1 upon the addition of compounds,
Table S17: RMSD values of for heavy atoms between the co-crystallized benzene-1,2,4-tricarboxylic acid (6DIE)
and the docked molecule, Table S18: Scores of the scoring function from the docked ligands with and without
water, Table S19: The calculated molecular descriptors for the ligands, Table S20: Definition of lead-like, drug-like
and Known drug space (KDS) in terms of molecular descriptors. The values given are the maxima for each
descriptor for the volumes of chemical space used, Table S21: Known drug index calculated.
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